HYBRID TOXIN

Abstract: The present invention provides, inter allia, a B.t. hybrid toxin fragment comprising at its C-terminal domain III of a first Cry protein or a part of the domain or a protein substantially similar to the domain, with the proviso that the N-terminal region of the fragment is the N-terminal region of a second Cry protein or a part of the region or a protein substantially similar to the region.

Description: HYBRID TOXIN The present invention relates to hybrid toxin fragments, and toxins comprising them, derived from Bacillus thuringiensis insecticidal crystal proteins. Bacillus thuringiensis (hereinafter B.t.) is capable of producing proteins that accumulate intra- cellularly as crystals. These crystal proteins are toxic to a number of insect larvae. Based on sequence homology and insecticidal specificity, crystal proteins have been categorized into different classes. Best studied are the Cryl class of proteins which are produced as 140 kDa pro-toxins and are active towards lepidopterans. To some extent the mode of action of crystal proteins has been elucidated. After oral uptake the crystals dissolve in the alkaline environment of the larval midgut. The solubilized proteins are subsequently processed by midgut proteinases to a proteinase-resistant toxic fragment of about 65kDa which binds to receptors on epithelial cells of the insect midgut and penetrates the cell membrane. This eventually leads to bursting of the cells and death of the larvae. The activity spectrum of a particular crystal protein is to a large extent determined by the occurrence of receptors on the midgut epithelial cells of susceptible insects. The said spectrum is co-determined by the efficiency of solubilization of the crystal protein and its proteolytic activation in vivo. The importance of the binding of the crystal protein to midgut epithelial receptors is further demonstrated where insects have developed resistance to one of the crystal proteins in that the binding of crystal proteins to midgut epithelial cells in resistant insects is significantly reduced. Toxic fragments of crystal proteins are thought to be composed of three distinct structural domains. Domain I, the most N-terminal domain, consists of 7 α-helices. Domain II comprises 3 β-sheets and domain IE (the most C-terminal) folds into a β-sandwich. If projected on Cryl sequences, domain I runs from about amino acid residue 28 to 260/domain II from about 260 to 460 and domain HI from about 460 to 600. The present invention concerns hybrid crystal proteins particularly, though not exclusively, involving CrylC and CrylE or CrylA. The nucleotide sequence of the CrylC gene from B.t. sub.sp. entomocidus 60.5 is given in SEQ ID. No. 1, and the corresponding amino acid sequence of the protein encoded by the said nucleotide sequence is given in SEQ ID No. 2. The nucleotide sequence of the CrylE gene from B.t. sub. sp. kenyae 4FI is given in SEQ ED. No. 3, and the corresponding amino acid sequence of the protein encoded by the said nucleotide sequence is given in SEQ ID No.4. These proteins are toxic to lepidopterans, but within this order of insects, each protein has different specificity. CrylC is particularly active against S.exigua and M.brassicae. According to the present invention there is provided a B.t. hybrid toxin fragment comprising at its C-terminal domain m of a first Cry protein or a part of the domain or a protein substantially similar to the domain, with the proviso that the N-terminal region of the fragment is the N-terminal region of a second Cry protein or a part of the region or a protein substantially similar to the region. A preferred fragment is one which does not bind to the CrylC binding site in an insect gut when it comprises at its C-terminal domain HI of CrylC or a part of the domain or a protein substantially similar to the domain; or one which does not bind to a Cry LA binding site when it comprises at its C-terminal domain IE of CrylA or a part of the domain or a protein substantially similar to the domain. By substantially similar is meant pure proteins having an amino acid sequence which is at least 75% similar to the sequence of the proteins according to the invention. It is preferred that the degree of similarity is at least 85%, more preferred that the degree of similarity is at least 90% and still more preferred that the degree of similarity is at least 95%. In the context of the present invention, two amino acid sequences with at least 75%, 85%, 90% or 95% similarity to each other have at least 75%, 85%, 90%, or 95% identical or conservatively replaced amino acid residues in a like position when aligned optimally allowing for up to 6 gaps with the proviso that in respect of the gaps a total not more than 15 amino acid residues are affected. For the purpose of the present invention conservative replacements may be made between amino acids within the following groups: (i) Serine, and Threonine; (ii) Glutamic acid and Aspartic acid; (iii) Arginine and Lysine; (iv) Asparagine and Glutamine; (v) Isoleucine, Leucine, Naline and Methionine; (vi) Phenylalanine, Tyrosine and Tryptophan (vii) Alanine and Glycine with the proviso that in SEQ ID No. 6 Ser and Tyr are conservative replacements at position 620, and Ala and Glu are conservative replacements at position 618; and that in SEQ ID No. 8 Ser and Tyr are conservative replacements at position 627, and Ala and Glu are conservative replacements at position 625. By "part" of a protein is meant a peptide comprised by the said protein and having at least 80% of the consecutive sequence thereof. By "binding site" is meant a site on a molecule wherein the binding between site and toxin is reversible such that the Ka between site and toxin is in the order of at least 10 4 dm 3 mole * . The toxin fragment may comprise at its N-terminal the N-terminal region of any insecticidal proteins from B.t. being commonly known as "Cry" or "Cyt", including: CryΙA(a), CryIA(b) CryΙA(c), CrylB, CrylC, CrylD, CrylE, CrylF, CrylG, CryTH, CryϋA, CryHB, CryHC, CrylllA, CrylLIB, CryΙIIB(b), CrylVA, CrylNB, CrylVC, CryIND, CYTA, CryXl(mC), CryX2(πiD), CryX3, CryV, and CryX4; or a part of the region, or a protein substantially similar to the region, and that the C-terminal of the fragment is domain ul of CrylC or a part of the domain or a protein substantially similar to the domain. Thus the fragment may comprise domain II of CrylE, CrylB, Cry ID or CrylA, or a part of the domain or a protein substantially similar to the domain, and domain LU of CrylC or a part of the said domain HI or a protein substantially similar to the said domain ET. It is particularly preferred that the fragment comprises domains I and E of CrylE, CrylB, CrylD or CrylA or a part thereof or a protein substantially similar to the said domains, and domain IE of CrylC or a part thereof or a protein substantially similar to the said domain El. It is most preferred that the toxin fragment comprises a region at its C-terminus comprising the sequence from amino acid position 454 to position 602 of CrylC, or a sequence substantially similar to the said sequence. The fragment may comprise a region at its C- terminus comprising the sequence from amino acid position 478 to 602 of Cry IC, or a sequence substantially similar to the said sequence, with the proviso that if the sequence comprising amino acids 478 to 602 of CrylC is fused directly to the C-terminus of domain II of CrylA, CrylB, CryE) or CrylE then the folding of the fusion product is satisfactory to yield an insecticidal component of the fragment. The skilled man will recognize that it may be necessary to add a peptide region to the C-terminus of domain E which spaces the C- terminal region of CrylC apart thus enabling it to fold in such a way as to exhibit insecticidal activity. It is most particularly preferred that the toxin fragment according to the invention comprises either: i) an amino acid sequence from about amino acid 1 to about amino acid 620 in SEQ ID No. 6, or an amino acid sequence from about amino acid 1 to about amino acid 620 in SEQ ID No. 6, wherein with respect to the said sequence, at least one of the following alterations is present: He at position 609 is replaced with Leu; Ala at position 618 is replaced with Glu; Ser at position 620 is replaced with Tyr, or ii) an amino acid sequence from about amino acid 1 to about amino acid 627 in SEQ ID No. 8, or an amino acid sequence from about amino acid 1 to about amino acid 627 in SEQ ID No. 8, wherein with respect to the said sequence, at least one of the following alterations is present: ϋe at position 616 is replaced with Leu; Ala at position 625 is replaced with Glu; Ser at position 627 is replaced with Tyr. Whatever amino acid alterations are permitted, however, one or more of the following residues - indicated sequence-wise with respect to the CrylC sequence - is invariable: Phe (501); Nal (478) Trp (479) and Thr (486). The invention also includes a hybrid toxin comprising the above disclosed fragment or a toxin at least 85% similar to such a hybrid toxin which has substantially similar insecticidal activity, or receptor binding properties. The invention still further includes pure proteins which are at least 90% identical to the toxin fragments or hybrid toxins according to the invention. The invention still further includes recombinant DΝA comprising a sequence encoding a protein having an amino acid sequence of the above disclosed toxins or fragments thereof. The invention still further includes recombinant DΝA comprising the sequence from about nucleotide 1 to about nucleotide 1860 given in SEQ ID. No. 5 or DNA similar thereto encoding a substantially similar protein, or recombinant DNA comprising the sequence from about nucleotide 1 to about nucleotide 1881 in SEQ ID No. 7 or DNA similar thereto encoding a substantially similar protein. By similar DNA is meant a test sequence which is capable of hybridizing to the inventive recombinant sequence. When the test and inventive sequences are double stranded the nucleic acid constituting the test sequence preferably has a TM within 20°C of that of the inventive sequence. In the case that the test and inventive sequences are mixed together and denatured simultaneously, the TM values of the sequences are preferably within 10°C of each other. More preferably the hybridization is performed under stringent conditions, with either the test or inventive DNA preferably being supported. Thus either a denatured test or inventive sequence is preferably first bound to a support and hybridization is effected for a specified period of time at a temperature of between 50 and 70°C in double strength citrate buffered saline containing 0.1%SDS followed by rinsing of the support at the same temperature but with a buffer having a reduced SC concentration. Depending upon the degree of stringency required, and thus the degree of similarity of the sequences, such reduced concentration buffers are typically single strength SC containing 0.1%SDS, half strength SC containing 0.1%SDS and one tenth strength SC containing 0.1%SDS. Sequences having the greatest degree of similarity are those the hybridization of which is least affected by washing in buffers of reduced concentration. It is most preferred that the test and inventive sequences are so similar that the hybridization between them is substantially unaffected by washing or incubation in one tenth strength sodium citrate buffer containing 0.1%SDS. The recombinant DNA may further encode a protein having herbicide resistance, plant growth-promoting, anti-fungal, anti bacterial, anti-viral and/or anti-nematode properties. In the case that the DNA is to be introduced into a heterologous organism it may be modified to remove known mRNA instability motifs (such as AT rich regions) and polyadenylation signals, and or codons which are preferred by the organism into which the recombinant DNA is to be inserted may be used so that expression of the thus modified DNA in the said organism yields substantially similar protein to that obtained by expression of the unmodified recombinant DNA in the organism in which the protein components of the hybrid toxin or toxin fragments are endogenous. The invention still further includes a DNA sequence which is complementary to one which hybridizes under stringent conditions with the recombinant DNA according to the invention. Also included in the present invention are: a vector containing such a recombinant (or complementary thereto) DNA sequence; a plant or micro-organism which includes, and enables expression of such DNA; plants transformed with such DNA; the progeny of such plants which contain the DNA stably incorporated and hereditable in a Mendelian manner, and/or the seeds of such plants and such progeny. The invention still further includes protein derived from expression of the said DNA, and insecticidal protein produced by expression of the recombinant DNA within plants transformed therewith. The invention still further includes an insecticidal composition containing one or more of the toxin fragments or toxins comprising them according to the invention; a process for combatting insects which comprises exposing them to such fragments or toxins or compositions, and an extraction process for obtaining insecticidal proteins from organic material containing them comprising submitting the material to maceration and solvent extraction. The invention will be further apparent from the following description, which describes the production of B.t. hybrid toxin fragments according to the invention, taken in conjunction with the associated drawings and sequence listings. Figure 1 shows the generation of hybrid crystal protein genes via in vivo recombination. Tandem plasmids (pBD560 and pBD 650) carrying two truncated crystal protein genes in direct repeat orientation are constructed. The 5' located gene (open bar) lacks the protoxin encoding region (solid bar) and of the 3' located gene (dashed bar) part of the domain I encoding region is deleted. In vivo recombination between homologous regions (domain II and El) occurs in recA + strain JMIOI. Selection against non- recombinants by digestion with Nøtl and BαmHI and subsequent transformation results in sets of plasmids encoding hybrid crystal proteins. Figure 2 shows the alignment of amino acid residues 420 to 630 of CrylE and CrylC. The border between domain E and IE is indicated. Only amino acid residues of CrylC which differ from CrylE are depicted, identical residues are indicated by a dot. The positions of cross-over (G27, H13, H7, H8 H17 and H21) in the CrylE-CrylC hybrid toxin fragments according to the invention are indicated on the Figure. Figure 3 shows the alignment of amino acid residues 420 to 630 of CrylE and CrylC. The border between domain E and El is indicated. Only amino acid residues of CrylC which differ from CrylE are depicted, identical residues are indicated by a dot. The positions of cross-over (F59, F71, F26, and E7) in the CrylC-CrylE hybrid toxin fragments are indicated on the Figure. Figure 4 shows the results of some heterologous competition experiments. Biotinylated CrylC (panel A) and G27 (panel B) are incubated with S. exigua BBMV vesicles in the absence (lanes a) or presence of an excess of unlabelled protein as indicated. After the incubation, the vesicles are washed, loaded on a SDS-polyacrylamide gel and blotted to a nitrocellulose membrane. Biotonylated crystal proteins, re-isolated with the vesicles, were are visualized using streptavidin-peroxidase conjugate and are indicated on the Figure with an arrow head. Figure 5 shows the plasmid map of pSB456 which encodes the G27 hybrid toxin fragment and is used to transform the crystal toxin minus strain B.t. 51. SEQ ED. No. 1 shows the nucleotide sequence of the CrylC gene from B.t. sub.sp. entomocidus 60.5. SEQ ID No. 2 shows the amino acid sequence of the protein encoded by the CrylC gene shown in SEQ ID No. 1. SEQ ED No. 3 shows the nucleotide sequence of the CrylE gene from B.t. sub.sp. kenyae 4FI. SEQ ED No. 4 shows the amino acid sequence of the protein encoded by the CrylE gene shown in SEQ ED No. 3. SEQ ED No. 5 shows the nucleotide sequence encoding a preferred CrylE/CrylC B.t. hybrid toxin fragment according to the invention. SEQ ID No. 6 shows the amino acid sequence of the protein encoded by the nucleotide sequence shown in SEQ ED No. 5. SEQ ED No.7 shows the nucleotide sequence of a CrylA/CrylC hybrid toxin fragment according to the invention. SEQ ID No. 8 shows the amino acid sequence of the protein encoded by the nucleotide sequence depicted in SEQ ED No.7. Production of plasmids encoding Hybrid toxin fragments In the production of plasmids carrying the CrylC or CrylE genes, Escherichia coli XLI-blue (Stratagene Inc.) is used as plasmid host except in cases were JM101 is used as recA background. A vector for the expression of crystal proteins in E.coli is derived fro pKK233-2 (Pharmacia LKB Biotechnology). The size of ρKK233-2 is reduced by deleting an ECORI-PVHE fragment carrying the gene encoding tetracycline resistance. Subsequently a 6 bp Xhol linker is ligated into the HindΩl site resulting in pBDIO. Plasmid BK+ is created by insertion of a BglTL linker in the Sαcl site of Bluescript SK+ (Stratagene Inc.). The polylinker of BK+ from BglΩ. to Xhol is introduced between the Ncol-Xhol site in pBDIO. The resulting expression vector pBDll contains the highly expressed trc promoter, the lacL ribosome binding site and ATG initiation codon. The initiation codon overlaps with a Ncol site and is followed by the polylinker to facilitate insertions into the vector. Transcription is terminated by the rrπB transcription terminator. The cloning of the crylC and crylE genes from B.t. subsp. entomocidus 60.5 and kenya 4F1 respectively, is as described previously (Honee et al., 1990 (Appl. Environ. Microbiol. 56, pp 823-825); Nisser et al, 1990 (J. Bacteriol. 172, pp 6783-6788)). For cloning purposes, an Ncol site overlapping with the start codon of crylC is created by in vitro mutagenesis. A Bg site is created directly downstream of the translation termination codon of crylC by site directed mutagenesis, resulting in the sequence ATAAGATCTGTT (stop- codon underlined). The ΝcoI-BglE fragment containing the crylC coding region is ligated into pBDll, resulting in CrylC expression plasmid pBD150. pBD155 is a derivative of pBD150, in which the polylinker sequences 3' of crylC are deleted. A Drαl fragment from pEM14 (Nisser et al., 1990) containing the complete cryBE gene is cloned in the EcoRV site of SK+, resulting in plasmid pEM15. Subsequently, an Ncol site is introduced by site directed mutagenesis at the startcodon of the gene, and crylE is transferred as an Ncoϊ-Xhol fragment to pBDll resulting in CrylE expression plasmid pBD160. Plasmids carrying only toxic fragment encoding regions of the cryl genes are constructed. BgM linkers are ligated to Xm l sites present at bp position 1835 of crylC, and to the HgiAI site at position 1839 of crylE. Subsequently, Ncol-BglΩ. fragments containing the cryl (1835 bp) and crylE (1839 bp) toxic fragment encoding regions are ligated into pBDll resulting in pBD151 and pBD161 respectively as described below. Tandem plasmids used for the generation of crylC-crylE hybrid genes are constructed as follows. BamHI linkers are ligated to pBD160 digested with Hpal. This DNA is incubated with BamHI and Xήol and the truncated crylE gene running from bp 704 is ligated into pBD151 resulting in pBD560. To construct a tandem plasmid for the generation of crylE- crylC hybrids, pBD155 is digested with Nsi and Xhol. The fragment carrying the truncated crylC gene, running from bp 266, is ligated into PstVXhol digested pBD161, resulting in plasmid pBD650. Due to polylinker sequences, unique Notl and BamHI restriction sites are present between the truncated cryl genes present in the tandem plasmids pBD560 and pBD650. DNA manipulations and construction of hybrid toxins- All recombinant DNA techniques are as described by Sambrook et al. 1989 (in "Molecular Cloning, A Laboratory Manual: Cold Spring Harbour Press, Cold Spring Harbour), DNA sequencing is performed by the dideoxytriphosphate method with fluorescent dyes attached to the dideoxynucleotides. Analysis is automated by using an Applied Biosystems 370A nucleotide sequence analyzer. The homology present between cryl genes permits intramolecular recombination in vivo. Two tandem plasmids are created by, each carrying two truncated crystal protein genes overlapping only in domains E and El. Therefore, recombination occurs only in regions encoding domains E and El. In frame recombinations, which can be selected for by restriction enzyme digestion, generate plasmids which express full size 140 kDa hybrid protoxins. To generate in vivo recombinants, a tandem plasmid (either pBD560 or pBD650; Figure 2) is transferred to JM101. 5 μg of DNA is isolated from independently generated recombinants and is digested with Notl and BαmHI cutting between the two truncated cryl genes to select against non-recombinants and the DΝA is transformed to E.coli XLl-blue. 5 single colonies are grown and protein patterns and plasmid content are analysed. CrylC-CrylE and CrylE-CrylC hybrid toxins are generated using the tandem plasmid pBD560 and pBD650 respectively which are allowed to recombine in a recA+ background DNA is isolated, digested and transferred to recA- strain as described above. 100 colonies of 20 independent experiments are analyzed on SDS-PAGE. 85% of thes clones produce a 140 kDa protein indicating in frame recombinations between crylC an crylE, and crylE and crylC respectively. In E.coli, Cryl proteins are produced as crystal which can be solubilized in vitro at high pH. Approximately 15% of hybrid toxins produce as above are solubilized at high pH. The recombinants producing soluble hybrid toxins are first classified using restriction enzymes, subsequently for each class the cross-over point o selected hybrids is determined by DNA sequence analysis. All cross-overs which resulted in soluble hybrid toxins occur in or very close to domain IE. Protein purification and analysis. Crystal proteins are isolated essentially as described by Convents et al (J. Biol. Chem. 265, pp 1369-1375; Eur. J. Biochem, 195, pp 631-635). Briefly, recombinant E.coli are grown at 30°C in 250 ml TB medium to an of 10-15. Crystals isolated from the E.coli lysate are solubilized during incubation for 2h in 20mM Na 2 CO 3 , 10 mM dithiothreitol, 100 mM NaCl, pHIO at 37 β C. The pH of the solution is lowered to 8 with Tris-HCl and incubated with trypsin. The toxin solution is dialysed against 20 mM Tris-HCl, 100 mM NaCl pH9. Subsequently the toxic fragment is purified on a Mono Q 5/5 column connected to a fast-protein liquid chromatography (FPLC) system (Pharmacia LKB Biotechnology). Proteins are separated by 7.5% sodium dodecyl sulfate-polyacrylamide gel electrophoreses. Biochemical analysis and isolation of 65 kDa toxic fragments. Isolated crystals of purified CrylC, CrylE and the hybrid proteins are solubilized at high p and incubated with trypsin. Like CrylC and CrylE, all soluble hybrid toxins with cross-over in domain IE are converted to stable 65 kDa fragments. The 65 kDa fragments can b purified using anion exchange chromatography under similar conditions as the parenta proteins. Hybrids F59 and F71 which have cross-overs in domain E, are completel degraded by trypsin. Apparently, although these hybrids do not precipitate as insolubl aggregates, trypsin cleavage sites buried in the parental proteins may become exposed t trypsin. Because of this phenomenon, no 65 kDa fragments are isolated from F59 and F71 Table 1 shows the constitution of 5 CrylE-CrylC hybrid toxins: (G27; H8; H17; H13; H7 an H21) and 4 CrylC-CryLE hybrid toxins (F59; F71; F26; E7) with reference to the CrylC an CrylE proteins from which they are derived. The amino acid sequences of the CryLE-Cryl toxins comprising the toxic fragments of the present invention run to amino acid 1189 of th CrylC parent protein. The amino acid sequences of the CrylC-CrylE hybrid toxins run t amino acid 1171 of the CrylE parent protein. Table 1 also shows the relative insecticidal effectiveness of these various hybrid toxins with respect to the CrylC and CrylE proteins. TABLE 1 TOX. a.a. IE a.a. IC M.sexta S. exigua M.brassicae. IC 0 28-627 ++ ++ ++ IE 29-612 0 ++ - - G27 1-474 478-627 ++ ++(+) +(+) H8 1-497 501-627 ++ - - H17 1-529 533-627 ++ - - H7 1-577 588-627 - - - H21 1-605 621-627 F59 421-612 1-423 - - - F71 428-612 1-430 - - - F26 455-612 (1171) 1-458 ++ - - E7 588-612 (1171) 1-602 -H- ++ ++ Table 1. Constitution and toxicity of hybrid toxins with respect to the parent proteins. Most bioassays were performed with purified toxin fragments. In case of crylC these run from about aa 28 to about aa 627, and in case of cryLE till 612. The length of complete protoxins is indicated between brackets. Insect toxicity assays and insecticidal activity of crylClcrylE hybrid gene products. Bacterial cultures are concentrated to OD^ 6.0 and 100 μl are spotted on 2 cm 2 of artificia diet in a 24-well tissue culture plate. Alternatively, diluted samples of purified toxins a applied to the diet. Second instar larvae of either S.exigua, M.brassicae or M.sexta are fe on this diet (16 per sample dilution) for 5 days, after which the larval weight is scored. The relative growth (EC50, the concentration giving 50% growth reduction) is determined by calculating the ratio between the mean weight of larvae grown on diet supplemented wit toxin and the mean weight of control larvae grown on a diet without toxin. M.sexta egg layers are supplied by Carolina Biological Supply Company, North Carolina, US. The toxic fragments encoded by the hybrid gene products are tested for activity towards three different insect species as described above. M.sexta is susceptible to both CrylC and CrylE. As may be anticipated from their sensitivity to trypsin, hybrids F59 and F71 are not active against this insect (Table 1). Although H7 is converted by trypsin to stable 65 kDa proteins, it is not toxic to M.sexta. All of the other hybrids given in Table 1 are toxic and are apparently in the native, biologically active conformation. The 65 kDa fragment of CrylC is highly toxic towards S.exigua and M.brassicae whereas CrylE is not. G27 (Table 1; Fig. 2), a CrylE-CrylC hybrid with a cross-over at the junction of domain II and El is active towards both insects. This demonstrates that domain El of CrylC confers full activity towards S.exigua and M.brassicae. Hybrid H8, which differs in only three amino acid residues (see Fig 3) from G27, although active against M.sexta, is not active against S.exigua and M.brassicae. F26 (Table 1, Figure 3), the reciprocal hybrid of G27, in which domain IE of CrylC has been exchanged by domain El of CrylE, is not active against S.exigua or M.brassicae. Apparently, although the protein is toxic to M.sexta, the CrylC sequences running from amino acid 28-462 are not sufficient to kill S.exigua and M.brassicae. Only when CrylC sequences up till amino acid residue 602 are present in the hybrid (E7), is insecticidal activity against these insects restored. The present disclosure indicates that amino acid residues from 478-602 of CrylC can confer high insecticidal activity to CrylE against S.exigua and M.brassicae. Biotinylation of crystal proteins and binding assays. Biotinylation is performed using biotin-N-hydroxysuccinimide ester essentially as described by the manufacturer (Amersham). Img of crystal protein is incubated with 40 μl biotinylation reagent in 50 mM NaHCO3, 150 mM NaCl pH8, for one hour at 20°C. The solution is loaded on a Sephadex 25 column equilibrated with the same buffer containing 0.1 % BSA to remove unbound biotin and samples of the fractions are spotted on a nitrocellulose membrane. Fractions containing biotinylated crystal proteins are visualized using streptavidine-peroxidase conjugate (Amersham) which catalyzes the oxidation of luminol, resulting in chemiluminescence (ECL, Amersham) and pooled. Brush border membrane vesicles are isolated as described by Wolfersberger et al. (1987) (Comp. Biochem. Physiol. 86a, pp 301-308) except that the vesicles are washed once more with isolation buffer containing 0.1% Tween 20. Binding of biotinylated crystal proteins to brush border membrane vesicles (100 μg ml) is performed in 100 μl of PBS containing 1% BSA, 0.1% Tween-20(pH 7.6). Vesicles (20ug vessicle protein) are incubated with lOng biotinylated crystal proteins in the presence or absence of 1000 fold excess of unlabelled crystal proteins for lhour at 20°C. Subsequently, the vesicles are re-isolated by centrifugation for 10 minutes at 14,000g in an Eppendorf centrifuge, washed twice with binding buffer, re-suspended in sample buffer, denatured by heating and loaded on 7.5 % polyacrylamide gels. After electrophoresis, proteins are blotted to nitrocellulose membranes and biotinylated crystal proteins which are re-isolated with the vesicles are visualized by incubation of the nitrocellulose with streptavidin-peroxidase conjugate (Amersham) which catalyzes the oxidation of luminol, resulting in chemiluminescence (ECL, Amersham). Since binding to epithelial gut cells is a key step in the mode of action of crystal proteins, the binding of crystal proteins to S. exigua brush border membrane vesicles is investigated in heterologous competition experiments. Competition experiments demonstrate that the binding of labeled CrylC (Figure 4A, lane a) and labelled F26 (not shown) can be outcompeted by an excess of both unlabelled CrylC (lane b) or F26 (lane e) but not with an excess of G27 (lane c) or CrylE (lane d). Furthermore, binding of labelled G27 (Figure 4B, land a) and labelled CryLE (not shown) can be outcompeted by an excess of G27 (lane b) or CrylE (lane d), but not with an excess of CrylC (lane a) or F26 (lane e). From these results it is concluded that G27 and CrylE recognize the same binding sites on 5. exigua midgut membranes and that these sites differ from those which are recognized by CrylC and F26. The toxicity and binding assays combined demonstrate that G27 is as toxic as CrylC but that it binds a receptor different therefrom. As insects can develop resistance against a crystal protein by changing receptor binding characteristics G27 may be used in resistance management programs as an alternative to CrylC. Expression of crylE crylC hybrid toxin genes in heterologous systems. The G27 cryLE/crylC hybrid toxin gene is expressed in E.coli and the gene product exhibits at least the same insecticidal activity (at least against Spodoptera) as CrylC. Moreover, the said product exhibits an increased such activity when expressed in a Bacillus thuringiensis strain (see below). The gene encoding the G27 hybrid toxin is introduced into a suitable shuttle vector system, which is then introduced into an appropriate B.t. host. Such transformed cells are then cultured and the resulting toxin from both whole cultures and purified crystals is assayed for insecticidal activity. Construction of a G27-containing shuttle vector, transformation of Bt51 and purification of toxin protein therefrom. The gene encoding hybrid G27 (3.4 kbb) is cleaved from a pKK233 E. coli expression plasmid using Ncol and Xhol. The Xftol site is filled in using the Klenow fragment of E. coli DΝA Polymerase I. The resulting fragment is ligated to NcoVSmal digested pSB635 (pBluescriptKS+, P cry - C , and the CrylA(c) transcription terminator). The resulting plasmid, pSB453 is digested with Apal and Notl yielding a 4.2 kbp fragment carrying the promoter, the hybrid G27 orf and the terminator. This fragment is ligated to ApaVNoΛ digested pSB634 (shuttle vector containing pBClό.l and pBluescriptKS+), yielding pSB456 (see Figure 5). Plasmid DΝA, isolated from E. coli DH10B, is used to transform the crystal toxin minus B.t. strain, Bt51. Positive isolates are tetracycline resistant, show the presence of pSB456, and contain large inclusions corresponding to a 135 kDa protein (as determined by SDS-PAGE. G27 hybrid toxin samples are prepared from cultures of transformed B.t.51 grown through sporulation at 30°C in CYS-Tc 10 media. Insecticidal bioassays (Table 2) are performed on both full whole cultures and on washed crystal protein preparations. Controls include Bt51 (pSB440), containing the CrylC toxin, and Bt51 (pSB636), containing CrylE. Toxin concentrations are estimated by SDS-PAGE. Table 2. Bioassay of the hybrid toxin G27 in comparison with CrylC and CrylE. The number of samples is given in parenthesis. The hybrid toxin G27 is about 50% more effective than either of CrylE or CrylC in respect of toxicity at least to Spodoptera sp. Toxin LC • 50 Whole Culture (ppt) Washed Crystal Protein (ppm) CrylC 56(2) 36(2) 40(4) 7.8(2) 8.1(4) CrylE 79(1) 78(1) 33(4) 11.1(6) 7.5(4) G27 29(2) 21(2) 25(4) 4.7(4) 6.0(4) Ratio (IC/G27) 1.93 1.71 1.60 1.66 1.35 Although the present invention has been particularly described with reference to the production of the G27 hybrid toxin, the skilled man will appreciate that many other hybrid toxins having improved insecticidal characteristics may be produced according to the present disclosure. SEQ ED Nos. 7 and 8, for example, depict further hybrid toxins according to the invention which have improved insecticidal activity. Hybrid toxins may be produced comprising domain IE of CrylC and an N-terminal of any other Cry protein. In terms of bioassays, the hybrid toxin carrying transformants may be grown in SOP media in order to expedite the assay procedures and reduce the volumes of material required. Moreover, the gene encoding G27 and/or other hybrid toxins according to the invention may be transferred into toxin-encoding strains of B.t. and/or integrated into the chromosome of selected strains of B.t. or indeed introduced into plant genomes to provide for insecticidal activity in situ within the plant per se. In this regard, it is particularly preferred that the recombinant DNA encoding the toxins is modified in that codons which are preferred by the plant into which the recombinant DNA is to be inserted are used so that expression of the thus modified DNA in the said plant yields substantially similar protein to that obtained by expression of the unmodified recombinant DNA in the organism in which the protein components of the hybrid toxin or toxin fragments are endogenous. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: (A) NAME: Sandoz Ltd (B) STREET: Lichtstrasse 35 (C) CITY: Basel (D) STATE: BS (E) COUNTRY: Switzerland (F) POSTAL CODE (ZIP) : CH-4002 (G) TELEPHONE: 061-324-1111 (H) TELEFAX: 061-322-7532 (A) NAME: Sandoz Patent GMBH (B) STREET: Humboltstrasse 3 (C) CITY: Lorrach (E) COUNTRY: Germany (F) POSTAL CODE (ZIP) : D-7850 (A) NAME: Sandoz Erfindungen Verwaltungsgesellschaft MBH (B) STREET: Br-αnnerstrasse 35 (C) CITY: Vienna (E) COUNTRY: Austria (F) POSTAL CODE (ZIP) : A-1230 (ii) TITLE OF INVENTION: Hybrid Toxin (iii) NUMBER OF SEQUENCES: 8 (iv) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentln Release #1.0, Version #1.25 (EPO) (2) INFORMATION FOR SEQ ID NO: 1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3567 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iii) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Bacillus thuringiensis (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..3567 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1: ATG GAG GAA AAT AAT CAA AAT CAA TGC ATA CCT TAC AAT TGT TTA AGT 48 Met Glu Glu Asn Asn Gin Asn Gin Cys He Pro Tyr Asn Cys Leu Ser 1 5 10 15 AAT CCT GAA GAA GTA CTT TTG GAT GGA GAA CGG ATA TCA ACT GGT AAT 96 Asn Pro Glu Glu Val Leu Leu Asp Gly Glu Arg He Ser Thr Gly Asn 20 25 30 TCA TCA ATT GAT ATT TCT CTG TCA CTT GTT CAG TTT CTG GTA TCT AAC 144 Ser Ser He Asp He Ser Leu Ser Leu Val Gin Phe Leu Val Ser Asn 35 40 45 TTT GTA CCA GGG GGA GGA TTT TTA GTT GGA TTA ATA GAT TTT GTA TGG 192 Phe Val Pro Gly Gly Gly Phe Leu Val Gly Leu He Asp Phe Val Trp 50 55 60 GGA ATA GTT GGC CCT TCT CAA TGG GAT GCA TTT CTA GTA CAA ATT GAA 240 Gly He Val Gly Pro Ser Gin Trp Asp Ala Phe Leu Val Gin He Glu 65 70 75 80 CAA TTA ATT AAT GAA AGA ATA GCT GAA TTT GCT AGG AAT GCT GCT ATT 288 Gin Leu He Asn Glu Arg He Ala Glu Phe Ala Arg Asn Ala Ala He 85 90 95 GCT AAT TTA GAA GGA TTA GGA AAC AAT TTC AAT ATA TAT GTG GAA GCA 336 Ala Asn Leu Glu Gly Leu Gly Asn Asn Phe Asn He Tyr Val Glu Ala 100 105 110 TTT AAA GAA TGG GAA GAA GAT CCT AAT AAT CCA GAA ACC AGG ACC AGA 384 Phe Lys Glu Trp Glu Glu Asp Pro Asn Asn Pro Glu Thr Arg Thr Arg 115 120 125 GTA ATT GAT CGC TTT CGT ATA CTT GAT GGG CTA CTT GAA AGG GAC ATT 432 Val He Asp Arg Phe Arg He Leu Asp Gly Leu Leu Glu Arg Asp He 130 135 140 CCT TCG TTT CGA ATT TCT GGA TTT GAA GTA CCC CTT TTA TCC GTT TAT 480 Pro Ser Phe Arg He Ser Gly Phe Glu Val Pro Leu Leu Ser Val Tyr 145 150 155 160 GCT CAA GCG GCC AAT CTG CAT CTA GCT ATA TTA AGA GAT TCT GTA ATT 528 Ala Gin Ala Ala Asn Leu His Leu Ala He Leu Arg Asp Ser Val He 165 170 175 TTT GGA GAA AGA TGG GGA TTG ACA ACG ATA AAT GTC AAT GAA AAC TAT 576 Phe Gly Glu Arg Trp Gly Leu Thr Thr He Asn Val Asn Glu Asn Tyr 180 185 190 AAT AGA CTA ATT AGG CAT ATT GAT GAA TAT GCT GAT CAC TGT GCA AAT 624 Asn Arg Leu He Arg His He Asp Glu Tyr Ala Asp His Cys Ala Asn 195 200 205 ACG TAT AAT CGG GGA TTA AAT AAT TTA CCG AAA TCT ACG TAT CAA GAT 672 Thr Tyr Asn Arg Gly Leu Asn Asn Leu Pro Lys Ser Thr Tyr Gin Asp 210 215 220 TGG ATA ACA TAT AAT CGA TTA CGG AGA GAC TTA ACA TTG ACT GTA TTA 720 Trp He Thr Tyr Asn Arg Leu Arg Arg Asp Leu Thr Leu Thr Val Leu 225 230 235 240 GAT ATC GCC GCT TTC TTT CCA AAC TAT GAC AAT AGG AGA TAT CCA ATT 768 Asp He Ala Ala Phe Phe Pro Asn Tyr Asp Asn Arg Arg Tyr Pro He 245 250 255 CAG CCA GTT GGT CAA CTA ACA AGG GAA GTT TAT ACG GAC CCA TTA ATT 816 Gin Pro Val Gly Gin Leu Thr Arg Glu Val Tyr Thr Asp Pro Leu He 260 265 270 AAT TTT AAT CCA CAG TTA CAG TCT GTA GCT CAA TTA CCT ACT TTT AAC 864 Asn Phe Asn Pro Gin Leu Gin Ser Val Ala Gin Leu Pro Thr Phe Asn 275 280 285 GTT ATG GAG AGC AGC GCA ATT AGA AAT CCT CAT TTA TTT GAT ATA TTG 912 Val Met Glu Ser Ser Ala He Arg Asn Pro His Leu Phe Asp He Leu 290 295 300 AAT AAT CTT ACA ATC TTT ACG GAT TGG TTT AGT GTT GGA CGC AAT TTT 960 Asn Asn Leu Thr He Phe Thr Asp Trp Phe Ser Val Gly Arg Asn Phe 305 310 315 320 TAT TGG GGA GGA CAT CGA GTA ATA TCT AGC CTT ATA GGA GGT GGT AAC 1008 Tyr Trp Gly Gly His Arg Val He Ser Ser Leu He Gly Gly Gly Asn 325 330 335 ATA ACA TCT CCT ATA TAT GGA AGA GAG GCG AAC CAG GAG CCT CCA AGA 1056 He Thr Ser Pro He Tyr Gly Arg Glu Ala Asn Gin Glu Pro Pro Arg 340 345 350 TCC TTT ACT TTT AAT GGA CCG GTA TTT AGG ACT TTA TCA AAT CCT ACT 1104 Ser Phe Thr Phe Asn Gly Pro Val Phe Arg Thr Leu Ser Asn Pro Thr 355 360 365 TTA CGA TTA TTA CAG CAA CCT TGG CCA GCG CCA CCA TTT AAT TTA CGT 1152 Leu Arg Leu Leu Gin Gin Pro Trp Pro Ala Pro Pro Phe Asn Leu Arg 370 375 380 GGT GTT GAA GGA GTA GAA TTT TCT ACA CCT ACA AAT AGC TTT ACG TAT 1200 Gly Val Glu Gly Val Glu Phe Ser Thr Pro Thr Asn Ser Phe Thr Tyr 385 390 395 400 CGA GGA AGA GGT ACG GTT GAT TCT TTA ACT GAA TTA CCG CCT GAG GAT 1248 Arg Gly Arg Gly Thr Val Asp Ser Leu Thr Glu Leu Pro Pro Glu Asp 405 410 415 AAT AGT GTG CCA CCT CGC GAA GGA TAT AGT CAT CGT TTA TGT CAT GCA 1296 Asn Ser Val Pro Pro Arg Glu Gly Tyr Ser His Arg Leu Cys His Ala 420 425 430 ACT TTT GTT CAA AGA TCT GGA ACA CCT TTT TTA ACA ACT GGT GTA GTA 1344 Thr Phe Val Gin Arg Ser Gly Thr Pro Phe Leu Thr Thr Gly Val Val 435 440 445 TTT TCT TGG ACG CAT CGT AGT GCA ACT CTT ACA AAT ACA ATT GAT CCA 1392 Phe Ser Trp Thr His Arg Ser Ala Thr Leu Thr Asn Thr He Asp Pro 450 455 460 GAG AGA ATT AAT CAA ATA CCT TTA GTG AAA GGA TTT AGA GTT TGG GGG 1440 Glu Arg He Asn Gin He Pro Leu Val Lys Gly Phe Arg Val Trp Gly 465 470 475 480 GGC ACC TCT GTC ATT ACA GGA CCA GGA TTT ACA GGA GGG GAT ATC CTT 1488 Gly Thr Ser Val He Thr Gly Pro Gly Phe Thr Gly Gly Asp He Leu 485 490 495 CGA AGA AAT ACC TTT GGT GAT TTT GTA TCT CTA CAA GTC AAT ATT AAT 1536 Arg Arg Asn Thr Phe Gly Asp Phe Val Ser Leu Gin Val Asn He Asn 500 505 510 TCA CCA ATT ACC CAA AGA TAC CGT TTA AGA TTT CGT TAC GCT TCC AGT 1584 Ser Pro He Thr Gin Arg Tyr Arg Leu Arg Phe Arg Tyr Ala Ser Ser 515 520 525 AGG GAT GCA CGA GTT ATA GTA TTA ACA GGA GCG GCA TCC ACA GGA GTG 1632 Arg Asp Ala Arg Val He Val Leu Thr Gly Ala Ala Ser Thr Gly Val 530 535 540 GGA GGC CAA GTT AGT GTA AAT ATG CCT CTT CAG AAA ACT ATG GAA ATA 1680 Gly Gly Gin Val Ser Val Asn Met Pro Leu Gin Lys Thr Met Glu He 545 550 555 560 GGG GAG AAC TTA ACA TCT AGA ACA TTT AGA TAT ACC GAT TTT AGT AAT 1728 Gly Glu Asn Leu Thr Ser Arg Thr Phe Arg Tyr Thr Asp Phe Ser Asn 565 570 575 CCT TTT TCA TTT AGA GCT AAT CCA GAT ATA ATT GGG ATA AGT GAA CAA 1776 Pro Phe Ser Phe Arg Ala Asn Pro Asp He He Gly He Ser Glu Gin 580 585 590 CCT CTA TTT GGT GCA GGT TCT ATT AGT AGC GGT GAA CTT TAT ATA GAT 1824 Pro Leu Phe Gly Ala Gly Ser He Ser Ser Gly Glu Leu Tyr He Asp 595 600 605 AAA ATT GAA ATT ATT CTA GCA GAT GCA ACA TTT GAA GCA GAA TCT GAT 1872 Lys He Glu He He Leu Ala Asp Ala Thr Phe Glu Ala Glu Ser Asp 610 615 620 TTA GAA AGA GCA CAA AAG GCG GTG AAT GCC CTG TTT ACT TCT TCC AAT 1920 Leu Glu Arg Ala Gin Lys Ala Val Asn Ala Leu Phe Thr Ser Ser Asn 625 630 635 640 CAA ATC GGG TTA AAA ACC GAT GTG ACG GAT TAT CAT ATT GAT CAA GTA 1968 Gin He Gly Leu Lys Thr Asp Val Thr Asp Tyr His He Asp Gin Val 645 650 655 TCC AAT TTA GTG GAT TGT TTA TCA GAT GAA TTT TGT CTG GAT GAA AAG 2016 Ser Asn Leu Val Asp Cys Leu Ser Asp Glu Phe Cys Leu Asp Glu Lys 660 665 670 CGA GAA TTG TCC GAG AAA GTC AAA CAT GCG AAG CGA CTC AGT GAT GAG 2064 Arg Glu Leu Ser Glu Lys Val Lys His Ala Lys Arg Leu Ser Asp Glu 675 680 685 CGG AAT TTA CTT CAA GAT CCA AAC TTC AGA GGG ATC AAT AGA CAA CCA 2112 Arg Asn Leu Leu Gin Asp Pro Asn Phe Arg Gly He Asn Arg Gin Pro 690 695 700 GAC CGT GGC TGG AGA GGA AGT ACA GAT ATT ACC ATC CAA GGA GGA GAT 2160 Asp Arg Gly Trp Arg Gly Ser Thr Asp He Thr He Gin Gly Gly Asp 705 710 715 720 GAC GTA TTC AAA GAG AAT TAC GTC ACA CTA CCG GGT ACC GTT GAT GAG 2208 Asp Val Phe Lys Glu Asn Tyr Val Thr Leu Pro Gly Thr Val Asp Glu 725 730 735 TGC TAT CCA ACG TAT TTA TAT CAG AAA ATA GAT GAG TCG AAA TTA AAA 2256 Cys Tyr Pro Thr Tyr Leu Tyr Gin Lys He Asp Glu Ser Lys Leu Lys 740 745 750 GCT TAT ACC CGT TAT GAA TTA AGA GGG TAT ATC GAA GAT AGT CAA GAC 2304 Ala Tyr Thr Arg Tyr Glu Leu Arg Gly Tyr He Glu Asp Ser Gin Asp 755 760 765 TTA GAA ATC TAT TTG ATC CGT TAC AAT GCA AAA CAC GAA ATA GTA AAT 2352 Leu Glu He Tyr Leu He Arg Tyr Asn Ala Lys His Glu He Val Asn 770 775 780 GTG CCA GGC ACG GGT TCC TTA TGG CCG CTT TCA GCC CAA AGT CCA ATC 2400 Val Pro Gly Thr Gly Ser Leu Trp Pro Leu Ser Ala Gin Ser Pro He 785 790 795 800 GGA AAG TGT GGA GAA CCG AAT CGA TGC GCG CCA CAC CTT GAA TGG AAT 2448 Gly Lys Cys Gly Glu Pro Asn Arg Cys Ala Pro His Leu Glu Trp Asn 805 810 815 CCT GAT CTA GAT TGT TCC TGC AGA GAC GGG GAA AAA TGT GCA CAT CAT 2496 Pro Asp Leu Asp Cys Ser Cys Arg Asp Gly Glu Lys Cys Ala His His 820 825 830 TCC CAT CAT TTC ACC TTG GAT ATT GAT GTT GGA TGT ACA GAC TTA AAT 2544 Ser His His Phe Thr Leu Asp He Asp Val Gly Cys Thr Asp Leu Asn 835 840 845 GAG GAC TTA GGT GTA TGG GTG ATA TTC AAG ATT AAG ACG CAA GAT GGC 2592 Glu Asp Leu Gly Val Trp Val He Phe Lys He Lys Thr Gin Asp Gly 850 855 860 CAT GCA AGA CTA GGG AAT CTA GAG TTT CTC GAA GAG AAA CCA TTA TTA 2640 His Ala Arg Leu Gly Asn Leu Glu Phe Leu Glu Glu Lys Pro Leu Leu 865 870 875 880 GGG GAA GCA CTA GCT CGT GTG AAA AGA GCG GAG AAG AAG TGG AGA GAC 2688 Gly Glu Ala Leu Ala Arg Val Lys Arg Ala Glu Lys Lys Trp Arg Asp 885 890 895 AAA CGA GAG AAA CTG CAG TTG GAA ACA AAT ATT GTT TAT AAA GAG GCA 2736 Lys Arg Glu Lys Leu Gin Leu Glu Thr Asn He Val Tyr Lys Glu Ala 900 905 910 AAA GAA TCT GTA GAT GCT TTA TTT GTA AAC TCT CAA TAT GAT AGA TTA 2784 Lys Glu Ser Val Asp Ala Leu Phe Val Asn Ser Gin Tyr Asp Arg Leu 915 920 925 CAA GTG GAT ACG AAC ATC GCG ATG ATT CAT GCG GCA GAT AAA CGC GTT 2832 Gin Val Asp Thr Asn He Ala Met He His Ala Ala Asp Lys Arg Val 930 935 940 CAT AGA ATC CGG GAA GCG TAT CTG CCA GAG TTG TCT GTG ATT CCA GGT 2880 His Arg He Arg Glu Ala Tyr Leu Pro Glu Leu Ser Val He Pro Gly 945 950 955 960 GTC AAT GCG GCC ATT TTC GAA GAA TTA GAG GGA CGT ATT TTT ACA GCG 2928 Val Asn Ala Ala He Phe Glu Glu Leu Glu Gly Arg He Phe Thr Ala 965 970 975 TAT TCC TTA TAT GAT GCG AGA AAT GTC ATT AAA AAT GGC GAT TTC AAT 2976 Tyr Ser Leu Tyr Asp Ala Arg Asn Val He Lys Asn Gly Asp Phe Asn 980 985 990 AAT GGC TTA TTA TGC TGG AAC GTG AAA GGT CAT GTA GAT GTA GAA GAG 3024 Asn Gly Leu Leu Cys Trp Asn Val Lys Gly His Val Asp Val Glu Glu 995 1000 1005 CAA AAC AAC CAC CGT TCG GTC CTT GTT ATC CCA GAA TGG GAG GCA GAA 3072 Gin Asn Asn His Arg Ser Val Leu Val He Pro Glu Trp Glu Ala Glu 1010 1015 1020 GTG TCA CAA GAG GTT CGT GTC TGT CCA GGT CGT GGC TAT ATC CTT CGT 3120 Val Ser Gin Glu Val Arg Val Cys Pro Gly Arg Gly Tyr He Leu Arg 1025 1030 1035 1040 GTC ACA GCA TAT AAA GAG GGA TAT GGA GAG GGC TGC GTA ACG ATC CAT 3168 Val Thr Ala Tyr Lys Glu Gly Tyr Gly Glu Gly Cys Val Thr He His 1045 1050 1055 GAG ATC GAA GAC AAT ACA GAC GAA CTG AAA TTC AGC AAC TGT GTA GAA 3216 Glu He Glu Asp Asn Thr Asp Glu Leu Lys Phe Ser Asn Cys Val Glu 1060 1065 1070 GAG GAA GTA TAT CCA AAC AAC ACA GTA ACG TGT AAT AAT TAT ACT GGG 3264 Glu Glu Val Tyr Pro Asn Asn Thr Val Thr Cys Asn Asn Tyr Thr Gly 1075 1080 1085 ACT CAA GAA GAA TAT GAG GGT ACG TAC ACT TCT CGT AAT CAA GGA TAT 3312 Thr Gin Glu Glu Tyr Glu Gly Thr Tyr Thr Ser Arg Asn Gin Gly Tyr 1090 1095 1100 GAC GAA GCC TAT GGT AAT AAC CCT TCC GTA CCA GCT GAT TAC GCT TCA 3360 Asp Glu Ala Tyr Gly Asn Asn Pro Ser Val Pro Ala Asp Tyr Ala Ser 1105 1110 1115 1120 GTC TAT GAA GAA AAA TCG TAT ACA GAT GGA CGA AGA GAG AAT CCT TGT 3408 Val Tyr Glu Glu Lys Ser Tyr Thr Asp Gly Arg Arg Glu Asn Pro Cys 1125 1130 1135 GAA TCT AAC AGA GGC TAT GGG GAT TAC ACA CCA CTA CCG GCT GGT TAT 3456 Glu Ser Asn Arg Gly Tyr Gly Asp Tyr Thr Pro Leu Pro Ala Gly Tyr 1140 1145 1150 GTA ACA AAG GAT TTA GAG TAC TTC CCA GAG ACC GAT AAG GTA TGG ATT 3504 Val Thr Lys Asp Leu Glu Tyr Phe Pro Glu Thr Asp Lys Val Trp He 1155 1160 1165 GAG ATC GGA GAA ACA GAA GGA ACA TTC ATC GTG GAT AGC GTG GAA TTA 3552 Glu He Gly Glu Thr Glu Gly Thr Phe He Val Asp Ser Val Glu Leu 1170 1175 1180 CTC CTT ATG GAG GAA 3567 Leu Leu Met Glu Glu 1185 (2) INFORMATION FOR SEQ ID NO: 2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1189 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: Met Glu Glu Asn Asn Gin Asn Gin Cys He Pro Tyr Asn Cys Leu Ser 1 5 10 15 Asn Pro Glu Glu Val Leu Leu Asp Gly Glu Arg He Ser Thr Gly Asn 20 25 30 Ser Ser He Asp He Ser Leu Ser Leu Val Gin Phe Leu Val Ser Asn 35 40 45 Phe Val Pro Gly Gly Gly Phe Leu Val Gly Leu He Asp Phe Val Trp 50 55 60 Gly He Val Gly Pro Ser Gin Trp Asp Ala Phe Leu Val Gin He Glu 65 70 75 80 Gin Leu He Asn Glu Arg He Ala Glu Phe Ala Arg Asn Ala Ala He 85 90 95 Ala Asn Leu Glu Gly Leu Gly Asn Asn Phe Asn He Tyr Val Glu Ala 100 .105 110 Phe Lys Glu Trp Glu Glu Asp Pro Asn Asn Pro Glu Thr Arg Thr Arg 115 120 125 Val He Asp Arg Phe Arg He Leu Asp Gly Leu Leu Glu Arg Asp He 130 135 140 Pro Ser Phe Arg He Ser Gly Phe Glu Val Pro Leu Leu Ser Val Tyr 145 150 155 160 Ala Gin Ala Ala Asn Leu His Leu Ala He Leu Arg Asp Ser Val He 165 170 175 Phe Gly Glu Arg Trp Gly Leu Thr Thr He Asn Val Asn Glu Asn Tyr 180 185 190 Asn Arg Leu He Arg His He Asp Glu Tyr Ala Asp His Cys Ala Asn 195 200 205 Thr Tyr Asn Arg Gly Leu Asn Asn Leu Pro Lys Ser Thr Tyr Gin Asp 210 215 220 Trp He Thr Tyr Asn Arg Leu Arg Arg Asp Leu Thr Leu Thr Val Leu 225 230 235 240 Asp He Ala Ala Phe Phe Pro Asn Tyr Asp Asn Arg Arg Tyr Pro He 245 250 255 Gin Pro Val Gly Gin Leu Thr Arg Glu Val Tyr Thr Asp Pro Leu He 260 265 270 Asn Phe Asn Pro Gin Leu Gin Ser Val Ala Gin Leu Pro Thr Phe Asn 275 280 285 Val Met Glu Ser Ser Ala He Arg Asn Pro His Leu Phe Asp He Leu 290 295 300 Asn Asn Leu Thr He Phe Thr Asp Trp Phe Ser Val Gly Arg Asn Phe 305 310 315 320 Tyr Trp Gly Gly His Arg Val He Ser Ser Leu He Gly Gly Gly Asn 325 330 335 He Thr Ser Pro He Tyr Gly Arg Glu Ala Asn Gin Glu Pro Pro Arg 340 345 350 Ser Phe Thr Phe Asn Gly Pro Val Phe Arg Thr Leu Ser Asn Pro Thr 355 360 365 Leu Arg Leu Leu Gin Gin Pro Trp Pro Ala Pro Pro Phe Asn Leu Arg 370 375 380 Gly Val Glu Gly Val Glu Phe Ser Thr Pro Thr Asn Ser Phe Thr Tyr 385 390 395 400 Arg Gly Arg Gly Thr Val Asp Ser Leu Thr Glu Leu Pro Pro Glu Asp 405 410 415 Asn Ser Val Pro Pro Arg Glu Gly Tyr Ser His Arg Leu Cys His Ala 420 425 430 Thr Phe Val Gin Arg Ser Gly Thr Pro Phe Leu Thr Thr Gly Val Val 435 440 445 Phe Ser Trp Thr His Arg Ser Ala Thr Leu Thr Asn Thr He Asp Pro 450 455 460 Glu Arg He Asn Gin He Pro Leu Val Lys Gly Phe Arg Val Trp Gly 465 470 475 480 Gly Thr Ser Val He Thr Gly Pro Gly Phe Thr Gly Gly Asp He Leu 485 490 495 Arg Arg Asn Thr Phe Gly Asp Phe Val Ser Leu Gin Val Asn He Asn 500 505 510 Ser Pro He Thr Gin Arg Tyr Arg Leu Arg Phe Arg Tyr Ala Ser Ser 515 520 525 Arg Asp Ala Arg Val He Val Leu Thr Gly Ala Ala Ser Thr Gly Val 530 535 540 Gly Gly Gin Val Ser Val Asn Met Pro Leu Gin Lys Thr Met Glu He 545 550 555 560 Gly Glu Asn Leu Thr Ser Arg Thr Phe Arg Tyr Thr Asp Phe Ser Asn 565 570 575 Pro Phe Ser Phe Arg Ala Asn Pro Asp He He Gly He Ser Glu Gin 580 585 590 Pro Leu Phe Gly Ala Gly Ser He Ser Ser Gly Glu Leu Tyr He Asp 595 600 605 Lys He Glu He He Leu Ala Asp Ala Thr Phe Glu Ala Glu Ser Asp 610 615 620 Leu Glu Arg Ala Gin Lys Ala Val Asn Ala Leu Phe Thr Ser Ser Asn 625 630 635 640 Gin He Gly Leu Lys Thr Asp Val Thr Asp Tyr His He Asp Gin Val 645 650 655 Ser Asn Leu Val Asp Cys Leu Ser Asp Glu Phe Cys Leu Asp Glu Lys 660 665 670 Arg Glu Leu Ser Glu Lys Val Lys His Ala Lys Arg Leu Ser Asp Glu 675 680 685 Arg Asn Leu Leu Gin Asp Pro Asn Phe Arg Gly He Asn Arg Gin Pro 690 695 700 Asp Arg Gly Trp Arg Gly Ser Thr Asp He Thr He Gin Gly Gly Asp 705 710 715 720 Asp Val Phe Lys Glu Asn Tyr Val Thr Leu Pro Gly Thr Val Asp Glu 725 730 735 Cys Tyr Pro Thr Tyr Leu Tyr Gin Lys He Asp Glu Ser Lys Leu Lys 740 745 750 Ala Tyr Thr Arg Tyr Glu Leu Arg Gly Tyr He Glu Asp Ser Gin Asp 755 760 765 Leu Glu He Tyr Leu He Arg Tyr Asn Ala Lys His Glu He Val Asn 770 775 780 Val Pro Gly Thr Gly Ser Leu Trp Pro Leu Ser Ala Gin Ser Pro He 785 790 795 800 Gly Lys Cys Gly Glu Pro Asn Arg Cys Ala Pro His Leu Glu Trp Asn 805 810 815 Pro Asp Leu Asp Cys Ser Cys Arg Asp Gly Glu Lys Cys Ala His His 820 825 830 Ser His His Phe Thr Leu Asp He Asp Val Gly Cys Thr Asp Leu Asn 835 840 845 Glu Asp Leu Gly Val Trp Val He Phe Lys He Lys Thr Gin Asp Gly 850 855 860 His Ala Arg Leu Gly Asn Leu Glu Phe Leu Glu Glu Lys Pro Leu Leu 865 870 875 880 Gly Glu Ala Leu Ala Arg Val Lys Arg Ala Glu Lys Lys Trp Arg Asp 885 890 895 Lys Arg Glu Lys Leu Gin Leu Glu Thr Asn He Val Tyr Lys Glu Ala 900 905 910 Lys Glu Ser Val Asp Ala Leu Phe Val Asn Ser Gin Tyr Asp Arg Leu 915 920 925 Gin Val Asp Thr Asn He Ala Met He His Ala Ala Asp Lys Arg Val 930 935 940 His Arg He Arg Glu Ala Tyr Leu Pro Glu Leu Ser Val He Pro Gly 945 950 955 ■ 960 Val Asn Ala Ala He Phe Glu Glu Leu Glu Gly Arg He Phe Thr Ala 965 970 975 Tyr Ser Leu Tyr Asp Ala Arg Asn Val He Lys Asn Gly Asp Phe Asn 980 985 990 Asn Gly Leu Leu Cys Trp Asn Val Lys Gly His Val Asp Val Glu Glu 995 1000 1005 Gin Asn Asn His Arg Ser Val Leu Val He Pro Glu Trp Glu Ala Glu 1010 1015 1020 Val Ser Gin Glu Val Arg Val Cys Pro Gly Arg Gly Tyr He Leu Arg 1025 1030 1035 1040 Val Thr Ala Tyr Lys Glu Gly Tyr Gly Glu Gly Cys Val Thr He His 1045 1050 1055 Glu He Glu Asp Asn Thr Asp Glu Leu Lys Phe Ser Asn Cys Val Glu 1060 1065 1070 Glu Glu Val Tyr Pro Asn Asn Thr Val Thr Cys Asn Asn Tyr Thr Gly 1075 1080 1085 Thr Gin Glu Glu Tyr Glu Gly Thr Tyr Thr Ser Arg Asn Gin Gly Tyr 1090 1095 1100 Asp Glu Ala Tyr Gly Asn Asn Pro Ser Val Pro Ala Asp Tyr Ala Ser 1105 1110 1115 1120 Val Tyr Glu Glu Lys Ser Tyr Thr Asp Gly Arg Arg Glu Asn Pro Cys 1125 1130 1135 Glu Ser Asn Arg Gly Tyr Gly Asp Tyr Thr Pro Leu Pro Ala Gly Tyr 1140 1145 1150 Val Thr Lys Asp Leu Glu Tyr Phe Pro Glu Thr Asp Lys Val Trp He 1155 1160 1165 Glu He Gly Glu Thr Glu Gly Thr Phe He Val Asp Ser Val Glu Leu 1170 1175 1180 Leu Leu Met Glu Glu 1185 (2) INFORMATION FOR SEQ ID NO: 3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3513 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iii) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Bacillus thuringiensis (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..3513 (xi) * SEQUENCE DESCRIPTION: SEQ ID NO: 3: ATG GAG ATA GTG AAT AAT CAG AAT CAA TGC GTG CCT TAT AAT TGT TTA 48 Met Glu He Val Asn Asn Gin Asn Gin Cys Val Pro Tyr Asn Cys Leu 1 5 10 15 AAT AAT CCT GAA AAT GAG ATA TTA GAT ATT GAA AGG TCA AAT AGT ACT 96 Asn Asn Pro Glu Asn Glu He Leu Asp He Glu Arg Ser Asn Ser Thr 20 25 30 GTA GCA ACA AAC ATC GCC TTG GAG ATT AGT CGT CTG CTC GCT TCC GCA 144 Val Ala Thr Asn He Ala Leu Glu He Ser Arg Leu Leu Ala Ser Ala 35 40 45 ACT CCA ATA GGG GGG ATT TTA TTA GGA TTG TTT GAT GCA ATA TGG GGG 192 Thr Pro He Gly Gly He Leu Leu Gly Leu Phe Asp Ala He Trp Gly 50 55 60 TCT ATA GGC CCT TCA CAA TGG GAT TTA TTT TTA GAG CAA ATT GAG CTA 240 Ser He Gly Pro Ser Gin Trp Asp Leu Phe Leu Glu Gin He Glu Leu 65 70 75 80 TTG ATT GAC CAA AAA ATA GAG GAA TTC GCT AGA AAC CAG GCA ATT TCT 288 Leu He Asp Gin Lys He Glu Glu Phe Ala Arg Asn Gin Ala He Ser 85 90 95 AGA TTG GAA GGG ATA AGC AGT CTG TAC GGA ATT TAT ACA GAA GCT TTT 336 Arg Leu Glu Gly He Ser Ser Leu Tyr Gly He Tyr Thr Glu Ala Phe 100 105 110 AGA GAG TGG GAA GCA GAT CCT ACT AAT CCA GCA TTA AAA GAA GAG ATG 384 Arg Glu Trp Glu Ala Asp Pro Thr Asn Pro Ala Leu Lys Glu Glu Met 115 120 125 CGT ACT CAA TTT AAT GAC ATG AAC AGT ATT CTT GTA ACA GCT ATT CCT 432 Arg Thr Gin Phe Asn Asp Met Asn Ser He Leu Val Thr Ala He Pro 130 135 140 CTT TTT TCA GTT CAA AAT TAT CAA GTC CCA TTT TTA TCA GTA TAT GTT 480 Leu Phe Ser Val Gin Asn Tyr Gin Val Pro Phe Leu Ser Val Tyr Val 145 150 155 160 CAA GCT GCA AAT TTA CAT TTA TCG GTT TTG AGA GAT GTT TCA GTG TTT 528 Gin Ala Ala Asn Leu His Leu Ser Val Leu Arg Asp Val Ser Val Phe 165 170 175 GGG CAG GCT TGG GGA TTT GAT ATA GCA ACA ATA AAT AGT CGT TAT AAT 576 Gly Gin Ala Trp Gly Phe Asp He Ala Thr He Asn Ser Arg Tyr Asn 180 185 190 GAT CTG ACT AGA CTT ATT CCT ATA TAT ACA GAT TAT GCT GTA CGC TGG 624 Asp Leu Thr Arg Leu He Pro He Tyr Thr Asp Tyr Ala Val Arg Trp 195 200 205 TAC AAT ACG GGA TTA GAT CGC TTA CCA CGA ACT GGT GGG CTG CGA AAC 672 Tyr Asn Thr Gly Leu Asp Arg Leu Pro Arg Thr Gly Gly Leu Arg Asn 210 215 220 TGG GCA AGA TTT AAT CAG TTT AGA AGA GAG TTA ACA ATA TCA GTA TTA 720 Trp Ala Arg Phe Asn Gin Phe Arg Arg Glu Leu Thr He Ser Val Leu 225 230 235 240 GAT ATT ATT TCT TTT TTC AGA AAT TAC GAT TCT AGA TTA TAT CCA ATT 768 Asp He He Ser Phe Phe Arg Asn Tyr Asp Ser Arg Leu Tyr Pro He 245 250 255 CCA ACA AGC TCC CAA TTA ACG CGG GAA GTA TAT ACA GAT CCG GTA ATT 816 Pro Thr Ser Ser Gin Leu Thr Arg Glu Val Tyr Thr Asp Pro Val He 260 265 270 AAT ATA ACT GAC TAT AGA GTT GGC CCC AGC TTC GAG AAT ATT GAG AAC 864 Asn He Thr Asp Tyr Arg Val Gly Pro Ser Phe Glu Asn He Glu Asn 275 280 285 TCA GCC ATT AGA AGC CCC CAC CTT ATG GAC TTC TTA AAT AAT TTG ACC 912 Ser Ala He Arg Ser Pro His Leu Met Asp Phe Leu Asn Asn Leu Thr 290 295 300 ATT GAT ACG GAT TTG ATT AGA GGT GTT CAC TAT TGG GCA GGG CAT CGT 960 He Asp Thr Asp Leu He Arg Gly Val His Tyr Trp Ala Gly His Arg 305 310 315 320 GTA ACT TCT CAT TTT ACA GGT AGT TCT CAA GTG ATA ACA ACC CCT CAA 1008 Val Thr Ser His Phe Thr Gly Ser Ser Gin Val He Thr Thr Pro Gin 325 330 335 TAT GGG ATA ACC GCA AAT GCG GAA CCA AGA CGA ACT ATT GCT CCT AGT 1056 Tyr Gly He Thr Ala Asn Ala Glu Pro Arg Arg Thr He Ala Pro Ser 340 345 350 ACT TTT CCA GGT CTT AAC CTA TTT TAT AGA ACA TTA TCA AAT CCT TTC 1104 Thr Phe Pro Gly Leu Asn Leu Phe Tyr Arg Thr Leu Ser Asn Pro Phe 355 360 365 TTC CGA AGA TCA GAA AAT ATT ACT CCT ACC TTA GGG ATA AAT GTA GTA 1152 Phe Arg Arg Ser Glu Asn He Thr Pro Thr Leu Gly He Asn Val Val 370 375 380 CAG GGA GTA GGG TTC ATT CAA CCA AAT AAT GCT GAA GTT CTA TAT AGA 1200 Gin Gly Val Gly Phe He Gin Pro Asn Asn Ala Glu Val Leu Tyr Arg 385 390 395 400 AGT AGG GGG ACA GTA GAT TCT CTT AAT GAG TTA CCA ATT GAT GGT GAG 1248 Ser Arg Gly Thr Val Asp Ser Leu Asn Glu Leu Pro He Asp Gly Glu 405 410 415 AAT TCA TTA GTT GGA TAT AGT CAT CGA TTA AGT CAT GTT ACA CTA ACC 1296 Asn Ser Leu Val Gly Tyr Ser His Arg Leu Ser His Val Thr Leu Thr 420 425 430 AGG TCG TTA TAT AAT ACT AAT ATA ACT AGC CTG CCA ACA TTT GTT TGG 1344 Arg Ser Leu Tyr Asn Thr Asn He Thr Ser Leu Pro Thr Phe Val Trp 435 440 445 ACA CAT CAC AGT GCT ACT AAT ACA AAT ACA ATT AAT CCA GAT ATT ATT 1392 Thr His His Ser Ala Thr Asn Thr Asn Thr He Asn Pro Asp He He 450 455 460 ACA CAA ATA CCT TTA GTG AAA GGA TTT AGA CTT GGT GGT GGC ACC TCT 1440 Thr Gin He Pro Leu Val Lys Gly Phe Arg Leu Gly Gly Gly Thr Ser 465 470 475 480 GTC ATT AAA GGA CCA GGA TTT ACA GGA GGG GAT ATC CTT CGA AGA AAT 1488 Val He Lys Gly Pro Gly Phe Thr Gly Gly Asp He Leu Arg Arg Asn 485 490 495 ACC ATT GGT GAG TTT GTG TCT TTA CAA GTC AAT ATT AAC TCA CCA ATT 1536 Thr He Gly Glu Phe Val Ser Leu Gin Val Asn He Asn Ser Pro He 500 505 510 ACC CAA AGA TAC CGT TTA AGA TTT CGT TAT GCT TCC AGT AGG GAT GCA 1584 Thr Gin Arg Tyr Arg Leu Arg Phe Arg Tyr Ala Ser Ser Arg Asp Ala 515 520 525 CGA ATT ACT GTA GCG ATA GGA GGA CAA ATT AGA GTA GAT ATG ACC CTT 1632 Arg He Thr Val Ala He Gly Gly Gin He Arg Val Asp Met Thr Leu 530 535 540 GAA AAA ACC ATG GAA ATT GGG GAG AGC TTA ACA TCT AGA ACA TTT AGC 1680 Glu Lys Thr Met Glu He Gly Glu Ser Leu Thr Ser Arg Thr Phe Ser 545 550 555 560 TAT ACC AAT TTT AGT AAT CCT TTT TCA TTT AGG GCT AAT CCA GAT ATA 1728 Tyr Thr Asn Phe Ser Asn Pro Phe Ser Phe Arg Ala Asn Pro Asp He 565 570 575 ATT AGA ATA GCT GAA GAA CTT CCT ATT CGT GGT GGT GAG CTT TAT ATA 1776 He Arg He Ala Glu Glu Leu Pro He Arg Gly Gly Glu Leu Tyr He 580 585 590 GAT AAA ATT GAA CTT ATT CTA GCA GAT GCA ACA TTT GAA GAA GAA TAT 1824 Asp Lys He Glu Leu He Leu Ala Asp Ala Thr Phe Glu Glu Glu Tyr 595 600 605 GAT TTG GAA AGA GCA CAG AAG GCG GTG AAT GCC CTG TTT ACT TCT ACA 1872 Asp Leu Glu Arg Ala Gin Lys Ala Val Asn Ala Leu Phe Thr Ser Thr 610 615 620 AAT CAA CTA GGG CTA AAA ACA GAT GTG ACG GAT TAT CAT ATT GAT CAA 1920 Asn Gin Leu Gly Leu Lys Thr Asp Val Thr Asp Tyr His He Asp Gin 625 630 635 640 GTT TCC AAT TTA GTT GAG TGT TTA TCG GAT GAA TTT TGT CTG GAT GAA -1968 Val Ser Asn Leu Val Glu Cys Leu Ser Asp Glu Phe Cys Leu Asp Glu 645 650 655 AAG AGA GAA TTA TCC GAG AAA GTC AAA CAT GCG AAG CGA CTC AGT GAT 2016 Lys Arg Glu Leu Ser Glu Lys Val Lys His Ala Lys Arg Leu Ser Asp 660 665 670 GAA CGG AAT TTA CTT CAA GAT CCA AAC TTC AGA GGG ATC AAT AGG CAA 2064 Glu Arg Asn Leu Leu Gin Asp Pro Asn Phe Arg Gly He Asn Arg Gin 675 680 685 CCA GAC CGT GGC TGG AGA GGA AGC ACG GAT ATT ACT ATC CAA GGT GGA 2112 Pro Asp Arg Gly Trp Arg Gly Ser Thr Asp He Thr He Gin Gly Gly 690 695 700 GAT GAC GTA TTC AAA GAG AAT TAC GTC ACA TTA CCG GGT ACC TTT GAT 2160 Asp Asp Val Phe Lys Glu Asn Tyr Val Thr Leu Pro Gly Thr Phe Asp 705 710 715 720 GAG TGC TAT CCA ACG TAT TTA TAT CAA AAA ATA GAT GAG TCG AAG TTA 2208 Glu Cys Tyr Pro Thr Tyr Leu Tyr Gin Lys He Asp Glu Ser Lys Leu 725 730 735 AAA GCT TAT ACC CGC TAT GAA TTA AGA GGG TAT ATC GAG GAT AGT CAA 2256 Lys Ala Tyr Thr Arg Tyr Glu Leu Arg Gly Tyr He Glu Asp Ser Gin 740 745 750 GAC TTA GAA ATC TAT TTA ATT CGC TAC AAT GCA AAA CAC GAG ACA GTA 2304 Asp Leu Glu He Tyr Leu He Arg Tyr Asn Ala Lys His Glu Thr Val 755 760 765 AAC GTG CCA GGT ACG GGT TCC TTA TGG CCG CTT TCA GCC CAA AGT CCA 2352 Asn Val Pro Gly Thr Gly Ser Leu Trp Pro Leu Ser Ala Gin Ser Pro 770 775 780 ATC GGA AAG TGT GGA GAA CCG AAT CGA TGC GCG CCA CAC CTT GAA TGG 2400 He Gly Lys Cys Gly Glu Pro Asn Arg Cys Ala Pro His Leu Glu Trp 785 790 795 800 AAT CCT AAT CTA GAT TGC TCC TGC AGA GAC GGG GAA AAA TGT GCC CAT 2448 Asn Pro Asn Leu Asp Cys Ser Cys Arg Asp Gly Glu Lys Cys Ala His 805 810 815 CAT TCC CAT CAT TTC TCC TTG GAC ATT GAT GTT GGA TGT ACA GAC TTA 2496 His Ser His His Phe Ser Leu Asp He Asp Val Gly Cys Thr Asp Leu 820 825 830 AAT GAG GAC TTA GGT GTA TGG GTG ATA TTC AAG ATT AAG ACA CAA GAT 2544 Asn Glu Asp Leu Gly Val Trp Val He Phe Lys He Lys Thr Gin Asp 835 840 845 GGC TAT GCA AGA CTA GGA AAT CTA GAG TTT CTC GAA GAG AAC CCA CTA 2592 Gly Tyr Ala Arg Leu Gly Asn Leu Glu Phe Leu Glu Glu Asn Pro Leu 850 855 860 TTA GGG GAA GCA CTA GCT CGT GTG AAA AGA GCG GAG AAA AAA TGG AGA 2640 Leu Gly Glu Ala Leu Ala Arg Val Lys Arg Ala Glu Lys Lys Trp Arg 865 870 875 880 GAC AAA TGC GAA AAA TTG GAA TGG GAA ACA AAT ATT GTT TAT AAA GAG 2688 Asp Lys Cys Glu Lys Leu Glu Trp Glu Thr Asn He Val Tyr Lys Glu 885 890 895 GCA AAA GAA TCT GTA GAT GCT TTA TTT GTA AAC TCT CAA TAT GAT AGA 2736 Ala Lys Glu Ser Val Asp Ala Leu Phe Val Asn Ser Gin Tyr Asp Arg 900 905 910 TTA CAA GCG GAT ACG AAT ATC GCG ATG ATT CAT GCG GCA GAT AAA CGC 2784 Leu Gin Ala Asp Thr Asn He Ala Met He His Ala Ala Asp Lys Arg 915 920 925 GTT CAT AGC ATT CGA GAA GCG TAT CTG CCA GAG CTG TCT GTG ATT CCG 2832 Val His Ser He Arg Glu Ala Tyr Leu Pro Glu Leu Ser Val He Pro 930 935 940 GGT GTC AAT GCG GCT ATT TTT GAA GAA TTA GAA GGG CGT ATT TTC ACT 2880 Gly Val Asn Ala Ala He Phe Glu Glu Leu Glu Gly Arg He Phe Thr 945 950 955 960 GCA TTC TCC CTA TAT GAT GCG AGA AAT GTC ATT AAA AAT GGC GAT TTC 2928 Ala Phe Ser Leu Tyr Asp Ala Arg Asn Val He Lys Asn Gly Asp Phe 965 970 975 AAT AAT GGC TTA TCA TGC TGG AAC GTG AAA GGG CAT GTA GAT GTA GAA 2976 Asn Asn Gly Leu Ser Cys Trp Asn Val Lys Gly His Val Asp Val Glu 980 985 990 GAA CAG AAC AAC CAT CGT TCG GTC CTT GTT GTT CCA GAA TGG GAA GCA 3024 Glu Gin Asn Asn His Arg Ser Val Leu Val Val Pro Glu Trp Glu Ala 995 1000 1005 GAA GTG TCA CAA GAA GTT CGT GTT TGT CCG GGT CGT GGC TAT ATC CTT 3072 Glu Val Ser Gin Glu Val Arg Val Cys Pro Gly Arg Gly Tyr He Leu 1010 1015 1020 CGT GTT ACA GCG TAC AAA GAG GGA TAT GGA GAG GGC TGT GTA ACG ATT 3120 Arg Val Thr Ala Tyr Lys Glu Gly Tyr Gly Glu Gly Cys Val Thr He 1025 1030 1035 1040 CAT GAG ATC GAA GAC AAT ACA GAC GAA CTG AAA TTC AGC AAC TGT GTA 3168 His Glu He Glu Asp Asn Thr Asp Glu Leu Lys Phe Ser Asn Cys Val 1045 1050 1055 GAA GAG GAA GTA TAT CCA AAC AAC ACG GTA ACG TGT AAT AAT TAT ACT 3216 Glu Glu Glu Val Tyr Pro Asn Asn Thr Val Thr Cys Asn Asn Tyr Thr 1060 1065 1070 GCG ACT CAA GAA GAA CAT GAG GGT ACG TAC ACT TCC CGT AAT CGA GGA 3264 Ala Thr Gin Glu Glu His Glu Gly Thr Tyr Thr Ser Arg Asn Arg Gly 1075 1080 1085 TAT GAC GAA GCC TAT GAA AGC AAT TCT TCT GTA CAT GCG TCA GTC TAT 3312 Tyr Asp Glu Ala Tyr Glu Ser Asn Ser Ser Val His Ala Ser Val Tyr 1090 1095 1100 GAA GAA AAA TCG TAT ACA GAT AGA CGA AGA GAG AAT CCT TGT GAA TCT 3360 Glu Glu Lys Ser Tyr Thr Asp Arg Arg Arg Glu Asn Pro Cys Glu Ser 1105 1110 1115 1120 AAC AGA GGA TAT GGG GAT TAC ACA CCA CTA CCA GCT GGC TAT GTG ACA 3408 Asn Arg Gly Tyr Gly Asp Tyr Thr Pro Leu Pro Ala Gly Tyr Val Thr 1125 1130 1135 AAA GAA TTA GAG TAC TTC CCA GAA ACC GAT AAG GTA TGG ATT GAG ATC 3456 Lys Glu Leu Glu Tyr Phe Pro Glu Thr Asp Lys Val Trp He Glu He 1140 1145 1150 GGA GAA ACG GAA GGA ACA TTC ATC GTG GAC AGC GTG GAA TTA CTT CTT 3504 Gly Glu Thr Glu Gly Thr Phe He Val Asp Ser Val Glu Leu Leu Leu 1155 1160 1165 ATG GAG GAA 3513 Met Glu Glu 1170 (2) INFORMATION FOR SEQ ID NO: 4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1171 amino acids (B) TYPE: amino acid. (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4: Met Glu He Val Asn Asn Gin Asn Gin Cys Val Pro Tyr Asn Cys Leu 1 5 10 15 Asn Asn Pro Glu Asn Glu He Leu Asp He Glu Arg Ser Asn Ser Thr 20 25 30 Val Ala Thr Asn He Ala Leu Glu He Ser Arg Leu Leu Ala Ser Ala 35 40 45 Thr Pro He Gly Gly He Leu Leu Gly Leu Phe Asp Ala He Trp Gly 50 55 60 Ser He Gly Pro Ser Gin Trp Asp Leu Phe Leu Glu Gin He Glu Leu 65 70 75 80 Leu He Asp Gin Lys He Glu Glu Phe Ala Arg Asn Gin Ala He Ser 85 90 95 Arg Leu Glu Gly He Ser Ser Leu Tyr Gly He Tyr Thr Glu Ala Phe 100 105 110 Arg Glu Trp Glu Ala Asp Pro Thr Asn Pro Ala Leu Lys Glu Glu Met 115 120 125 Arg Thr Gin Phe Asn Asp Met Asn Ser He Leu Val Thr Ala He Pro 130 135 140 Leu Phe Ser Val Gin Asn Tyr Gin Val Pro Phe Leu Ser Val Tyr Val 145 150 155 160 Gin Ala Ala Asn Leu His Leu Ser Val Leu Arg Asp Val Ser Val Phe 165 170 175 Gly Gin Ala Trp Gly Phe Asp He Ala Thr He Asn Ser Arg Tyr Asn 180 185 190 Asp Leu Thr Arg Leu He Pro He Tyr Thr Asp Tyr Ala Val Arg Trp 195 200 205 Tyr Asn Thr Gly Leu Asp Arg Leu Pro Arg Thr Gly Gly Leu Arg Asn 210 215 220 Trp Ala Arg Phe Asn Gin Phe Arg Arg Glu Leu Thr He Ser Val Leu 225 230 235 240 Asp He He Ser Phe Phe Arg Asn Tyr Asp Ser Arg Leu Tyr Pro He 245 250 255 Pro Thr Ser Ser Gin Leu Thr Arg Glu Val Tyr Thr Asp Pro Val He 260 265 270 Asn He Thr Asp Tyr Arg Val Gly Pro Ser Phe Glu Asn He Glu Asn 275 280 285 Ser Ala He Arg Ser Pro His Leu Met Asp Phe Leu Asn Asn Leu Thr 290 295 300 He Asp Thr Asp Leu He Arg Gly Val His Tyr Trp Ala Gly His Arg 305 310 315 320 Val Thr Ser His Phe Thr Gly Ser Ser Gin Val He Thr Thr Pro Gin 325 330 335 Tyr Gly He Thr Ala Asn Ala Glu Pro Arg Arg Thr He Ala Pro Ser 340 345 350 Thr Phe Pro Gly Leu Asn Leu Phe Tyr Arg Thr Leu Ser Asn Pro Phe 355 360 365 Phe Arg Arg Ser Glu Asn He Thr Pro Thr Leu Gly He Asn Val Val 370 375 380 Gin Gly Val Gly Phe He Gin Pro Asn Asn Ala Glu Val Leu Tyr Arg 385 390 395 400 Ser Arg Gly Thr Val Asp Ser Leu Asn Glu Leu Pro He Asp Gly Glu 405 410 415 Asn Ser Leu Val Gly Tyr Ser His Arg Leu Ser His Val Thr Leu Thr 420 425 430 Arg Ser Leu Tyr Asn Thr Asn He Thr Ser Leu Pro Thr Phe Val Trp 435 440 445 Thr His His Ser Ala Thr Asn Thr Asn Thr He Asn Pro Asp He He 450 455 460 Thr Gin He Pro Leu Val Lys Gly Phe Arg Leu Gly Gly Gly Thr Ser 465 470 475 480 Val He Lys Gly Pro Gly Phe Thr Gly Gly Asp He Leu Arg Arg Asn 485 490 495 Thr He Gly Glu Phe Val Ser Leu Gin Val Asn He Asn Ser Pro He 500 505 510 Thr Gin Arg Tyr Arg Leu Arg Phe Arg Tyr Ala Ser Ser Arg Asp Ala 515 520 525 Arg He Thr Val Ala He Gly Gly Gin He Arg Val Asp Met Thr Leu 530 535 540 Glu Lys Thr Met Glu He Gly Glu Ser Leu Thr Ser Arg Thr Phe Ser 545 550 555 560 Tyr Thr Asn Phe Ser Asn Pro Phe Ser Phe Arg Ala Asn Pro Asp He 565 570 575 He Arg He Ala Glu Glu Leu Pro He Arg Gly Gly Glu Leu Tyr He 580 585 590 Asp Lys He Glu Leu He Leu Ala Asp Ala Thr Phe Glu Glu Glu Tyr 595 600 605 Asp Leu Glu Arg Ala Gin Lys Ala Val Asn Ala Leu Phe Thr Ser Thr 610 615 620 Asn Gin Leu Gly Leu Lys Thr Asp Val Thr Asp Tyr His He Asp Gin 625 630 635 640 Val Ser Asn Leu Val Glu Cys Leu Ser Asp Glu Phe Cys Leu Asp Glu 645 650 655 Lys Arg Glu Leu Ser Glu Lys Val Lys His Ala Lys Arg Leu Ser Asp 660 665 670 Glu Arg Asn Leu Leu Gin Asp Pro Asn Phe Arg Gly He Asn Arg Gin 675 680 685 Pro Asp Arg Gly Trp Arg Gly Ser Thr Asp He Thr He Gin Gly Gly 690 695 700 Asp Asp Val Phe Lys Glu Asn Tyr Val Thr Leu Pro Gly Thr Phe Asp 705 710 715 720 Glu Cys Tyr Pro Thr Tyr Leu Tyr Gin Lys He Asp Glu Ser Lys Leu 725 730 735 Lys Ala Tyr Thr Arg Tyr Glu Leu Arg Gly Tyr He Glu Asp Ser Gin 740 745 750 Asp Leu Glu He Tyr Leu He Arg Tyr Asn Ala Lys His Glu Thr Val 755 760 765 Asn Val Pro Gly Thr Gly Ser Leu Trp Pro Leu Ser Ala Gin Ser Pro 770 775 780 He Gly Lys Cys Gly Glu Pro Asn Arg Cys Ala Pro His Leu Glu Trp 785 790 795 800 Asn Pro Asn Leu Asp Cys Ser Cys Arg Asp Gly Glu Lys Cys Ala His 805 810 815 His Ser His His Phe Ser Leu Asp He Asp Val Gly Cys Thr Asp Leu 820 825 830 Asn Glu Asp Leu Gly Val Trp Val He Phe Lys He Lys Thr Gin Asp 835 840 845 Gly Tyr Ala Arg Leu Gly Asn Leu Glu Phe Leu Glu Glu Asn Pro Leu 850 855 860 Leu Gly Glu Ala Leu Ala Arg Val Lys Arg Ala Glu Lys Lys Trp Arg 865 870 875 880 Asp Lys Cys Glu Lys Leu Glu Trp Glu Thr Asn He Val Tyr Lys Glu 885 890 895 Ala Lys Glu Ser Val Asp Ala Leu Phe Val Asn Ser Gin Tyr Asp Arg 900 905 910 Leu Gin Ala Asp Thr Asn He Ala Met He His Ala Ala Asp Lys Arg 915 920 925 Val His Ser He Arg Glu Ala Tyr Leu Pro Glu Leu Ser Val He Pro 930 935 940 Gly Val Asn Ala Ala He Phe Glu Glu Leu Glu Gly Arg He Phe Thr 945 950 955 960 Ala Phe Ser Leu Tyr Asp Ala Arg Asn Val He Lys Asn Gly Asp Phe 965 970 975 Asn Asn Gly Leu Ser Cys Trp Asn Val Lys Gly His Val Asp Val Glu 980 985 990 Glu Gin Asn Asn His Arg Ser Val Leu Val Val Pro Glu Trp Glu Ala 995 1000 1005 Glu Val Ser Gin Glu Val Arg Val Cys Pro Gly Arg Gly Tyr He Leu 1010 1015 1020 Arg Val Thr Ala Tyr Lys Glu Gly Tyr Gly Glu Gly Cys Val Thr He 1025 1030 1035 1040 His Glu He Glu Asp Asn Thr Asp Glu Leu Lys Phe Ser Asn Cys Val 1045 1050 1055 Glu Glu Glu Val Tyr Pro Asn Asn Thr Val Thr Cys Asn Asn Tyr Thr 1060 1065 1070 Ala Thr Gin Glu Glu His Glu Gly Thr Tyr Thr Ser Arg Asn Arg Gly 1075 1080 1085 Tyr Asp Glu Ala Tyr Glu Ser Asn Ser Ser Val His Ala Ser Val Tyr 1090 1095 1100 Glu Glu Lys Ser Tyr Thr Asp Arg Arg Arg Glu Asn Pro Cys Glu Ser 1105 1110 1115 1120 Asn Arg Gly Tyr Gly Asp Tyr Thr Pro Leu Pro Ala Gly Tyr Val Thr 1125 1130 1135 Lys Glu Leu Glu Tyr Phe Pro Glu Thr Asp Lys Val Trp He Glu He 1140 1145 1150 Gly Glu Thr Glu Gly Thr Phe He Val Asp Ser Val Glu Leu Leu Leu 1155 1160 1165 Met Glu Glu 1170 (2) INFORMATION FOR SEQ ID NO: 5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3558 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iii) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Hybrid sequence (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..3558 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5: ATG GAG ATA GTG AAT AAT CAG AAT CAA TGC GTG CCT TAT AAT TGT TTA - 48 Met Glu He Val Asn Asn Gin Asn Gin Cys Val Pro Tyr Asn Cys Leu 1 5 10 15 AAT AAT CCT GAA AAT GAG ATA TTA GAT ATT GAA AGG TCA AAT AGT ACT 96 Asn Asn Pro Glu Asn Glu He Leu Asp He Glu Arg Ser Asn Ser Thr 20 25 30 GTA GCA ACA AAC ATC GCC TTG GAG ATT AGT CGT CTG CTC GCT TCC GCA 144 Val Ala Thr Asn He Ala Leu Glu He Ser Arg Leu Leu Ala Ser Ala 35 40 45 ACT CCA ATA GGG GGG ATT TTA TTA GGA TTG TTT GAT GCA ATA TGG GGG 192 Thr Pro He Gly Gly He Leu Leu Gly Leu Phe Asp Ala He Trp Gly 50 55 60 TCT ATA GGC CCT TCA CAA TGG GAT TTA TTT TTA GAG CAA ATT GAG CTA 240 Ser He Gly Pro Ser Gin Trp Asp Leu Phe Leu Glu Gin He Glu Leu 65 70 75 80 TTG ATT GAC CAA AAA ATA GAG GAA TTC GCT AGA AAC CAG GCA ATT TCT 288 Leu He Asp Gin Lys He Glu Glu Phe Ala Arg Asn Gin Ala He Ser 85 90 95 AGA TTG GAA GGG ATA AGC AGT CTG TAC GGA ATT TAT ACA GAA GCT TTT 336 Arg Leu Glu Gly He Ser Ser Leu Tyr Gly He Tyr Thr Glu Ala Phe 100 105 110 AGA GAG TGG GAA GCA GAT CCT ACT AAT CCA GCA TTA AAA GAA GAG ATG 384 Arg Glu Trp Glu Ala Asp Pro Thr Asn Pro Ala Leu Lys Glu Glu Met 115 120 125 CGT ACT CAA TTT AAT GAC ATG AAC AGT ATT CTT GTA ACA GCT ATT CCT 432 Arg Thr Gin Phe Asn Asp Met Asn Ser He Leu Val Thr Ala He Pro 130 135 140 CTT TTT TCA GTT CAA AAT TAT CAA GTC CCA TTT TTA TCA GTA TAT GTT 480 Leu Phe Ser Val Gin Asn Tyr Gin Val Pro Phe Leu Ser Val Tyr Val 145 150 155 160 CAA GCT GCA AAT TTA CAT TTA TCG GTT TTG AGA GAT GTT TCA GTG TTT 528 Gin Ala Ala Asn Leu His Leu Ser Val Leu Arg Asp Val Ser Val Phe 165 170 175 GGG CAG GCT TGG GGA TTT GAT ATA GCA ACA ATA AAT AGT CGT TAT AAT 576 Gly Gin Ala Trp Gly Phe Asp He Ala Thr He Asn Ser Arg Tyr Asn 180 185 190 GAT CTG ACT AGA CTT ATT CCT ATA TAT ACA GAT TAT GCT GTA CGC TGG 624 Asp Leu Thr Arg Leu He Pro He Tyr Thr Asp Tyr Ala Val Arg Trp 195 200 205 TAC AAT ACG GGA TTA GAT CGC TTA CCA CGA ACT GGT GGG CTG CGA AAC 672 Tyr Asn Thr Gly Leu Asp Arg Leu Pro Arg Thr Gly Gly Leu Arg Asn 210 215 220 TGG GCA AGA TTT AAT CAG TTT AGA AGA GAG TTA ACA ATA TCA GTA TTA 720 Trp Ala Arg Phe Asn Gin Phe Arg Arg Glu Leu Thr He Ser Val Leu 225 230 235 240 GAT ATT ATT TCT TTT TTC AGA AAT TAC GAT TCT AGA TTA TAT CCA ATT 768 Asp He He Ser Phe Phe Arg Asn Tyr Asp Ser Arg Leu Tyr Pro He 245 250 255 CCA ACA AGC TCC CAA TTA ACG CGG GAA GTA TAT ACA GAT CCG GTA ATT 816 Pro Thr Ser Ser Gin Leu Thr Arg Glu Val Tyr Thr Asp Pro Val He 260 265 270 AAT ATA ACT GAC TAT AGA GTT GGC CCC AGC TTC GAG AAT ATT GAG AAC 864 Asn He Thr Asp Tyr Arg Val Gly Pro Ser Phe Glu Asn He Glu Asn 275 280 285 TCA GCC ATT AGA AGC CCC CAC CTT ATG GAC TTC TTA AAT AAT TTG ACC 912 Ser Ala He Arg Ser Pro His Leu Met Asp Phe Leu Asn Asn Leu Thr 290 295 300 ATT GAT ACG GAT TTG ATT AGA GGT GTT CAC TAT TGG GCA GGG CAT CGT 960 He Asp Thr Asp Leu He Arg Gly Val His Tyr Trp Ala Gly His Arg 305 310 315 320 GTA ACT TCT CAT TTT ACA GGT AGT TCT CAA GTG ATA ACA ACC CCT CAA 1008 Val Thr Ser His Phe Thr Gly Ser Ser Gin Val He Thr Thr Pro Gin 325 330 335 TAT GGG ATA ACC GCA AAT GCG GAA CCA AGA CGA ACT ATT GCT CCT AGT 1056 Tyr Gly He Thr Ala Asn Ala Glu Pro Arg Arg Thr He Ala Pro Ser 340 345 350 ACT TTT CCA GGT CTT AAC CTA TTT TAT AGA ACA TTA TCA AAT CCT TTC 1104 Thr Phe Pro Gly Leu Asn Leu Phe Tyr Arg Thr Leu Ser Asn Pro Phe 355 360 365 TTC CGA AGA TCA GAA AAT ATT ACT CCT ACC TTA GGG ATA AAT GTA GTA 1152 Phe Arg Arg Ser Glu Asn He Thr Pro Thr Leu Gly He Asn Val Val 370 375 380 CAG GGA GTA GGG TTC ATT CAA CCA AAT AAT GCT GAA GTT CTA TAT AGA 1200 Gin Gly Val Gly Phe He Gin Pro Asn Asn Ala Glu Val Leu Tyr Arg 385 390 395 400 AGT AGG GGG ACA GTA GAT TCT CTT AAT GAG TTA CCA ATT GAT GGT GAG 1248 Ser Arg Gly Thr Val Asp Ser Leu Asn Glu Leu Pro He Asp Gly Glu 405 410 415 AAT TCA TTA GTT GGA TAT AGT CAT CGA TTA AGT CAT GTT ACA CTA ACC 1296 Asn Ser Leu Val Gly Tyr Ser His Arg Leu Ser His Val Thr Leu Thr 420 425 430 AGG TCG TTA TAT AAT ACT AAT ATA ACT AGC CTG CCA ACA TTT GTT TGG 1344 Arg Ser Leu Tyr Asn Thr Asn He Thr Ser Leu Pro Thr Phe Val Trp 435 440 445 ACA CAT CAC AGT GCT ACT AAT ACA AAT ACA ATT AAT CCA GAT ATT ATT 1392 Thr His His Ser Ala Thr Asn Thr Asn Thr He Asn Pro Asp He He 450 455 460 ACA CAA ATA CCT TTA GTG AAA GGA TTT AGA GTT TGG GGG GGC ACC TCT 1440 Thr Gin He Pro Leu Val Lys Gly Phe Arg Val Trp Gly Gly Thr Ser 465 470 475 480 GTC ATT ACA GGA CCA GGA TTT ACA GGA GGG GAT ATC CTT CGA AGA AAT 1488 Val He Thr Gly Pro Gly Phe Thr Gly Gly Asp He Leu Arg Arg Asn 485 490 495 ACC TTT GGT GAT TTT GTA TCT CTA CAA GTC AAT ATT AAT TCA CCA ATT 1536 Thr Phe Gly Asp Phe Val Ser Leu Gin Val Asn He Asn Ser Pro He 500 505 510 ACC CAA AGA TAC CGT TTA AGA TTT CGT TAC GCT TCC AGT AGG GAT GCA 1584 Thr Gin Arg Tyr Arg Leu Arg Phe Arg Tyr Ala Ser Ser Arg Asp Ala 515 520 525 CGA GTT ATA GTA TTA ACA GGA GCG GCA TCC ACA GGA GTG GGA GGC CAA 1632 Arg Val He Val Leu Thr Gly Ala Ala Ser Thr Gly Val Gly Gly Gin 530 535 540 GTT AGT GTA AAT ATG CCT CTT CAG AAA ACT ATG GAA ATA GGG GAG AAC 1680 Val Ser Val Asn Met Pro Leu Gin Lys Thr Met Glu He Gly Glu Asn 545 550 555 560 TTA ACA TCT AGA ACA TTT AGA TAT ACC GAT TTT AGT AAT CCT TTT TCA 1728 Leu Thr Ser Arg Thr Phe Arg Tyr Thr Asp Phe Ser Asn Pro Phe Ser 565 570 575 TTT AGA GCT AAT CCA GAT ATA ATT GGG ATA AGT GAA CAA CCT CTA TTT 1776 Phe Arg Ala Asn Pro Asp He He Gly He Ser Glu Gin Pro Leu Phe 580 585 590 GGT GCA GGT TCT ATT AGT AGC GGT GAA CTT TAT ATA GAT AAA ATT GAA 1824 Gly Ala Gly Ser He Ser Ser Gly Glu Leu Tyr He Asp Lys He Glu 595 600 605 ATT ATT CTA GCA GAT GCA ACA TTT GAA GCA GAA TCT GAT TTA GAA AGA 1872 He He Leu Ala Asp Ala Thr Phe Glu Ala Glu Ser Asp Leu Glu Arg 610 615 620 GCA CAA AAG GCG GTG AAT GCC CTG TTT ACT TCT TCC AAT CAA ATC GGG 1920 Ala Gin Lys Ala Val Asn Ala Leu Phe Thr Ser Ser Asn Gin He Gly 625 630 635 640 TTA AAA ACC GAT GTG ACG GAT TAT CAT ATT GAT CAA GTA TCC AAT TTA 1968 Leu Lys Thr Asp Val Thr Asp Tyr His He Asp Gin Val Ser Asn Leu 645 650 655 GTG GAT TGT TTA TCA GAT GAA TTT TGT CTG GAT GAA AAG CGA GAA TTG 2016 Val Asp Cys Leu Ser Asp Glu Phe Cys Leu Asp Glu Lys Arg Glu Leu 660 665 670 TCC GAG AAA GTC AAA CAT GCG AAG CGA CTC AGT GAT GAG CGG AAT TTA 2064 Ser Glu Lys Val Lys His Ala Lys Arg Leu Ser Asp Glu Arg Asn Leu 675 680 685 CTT CAA GAT CCA AAC TTC AGA GGG ATC AAT AGA CAA CCA GAC CGT GGC 2112 Leu Gin Asp Pro Asn Phe Arg Gly He Asn Arg Gin Pro Asp Arg Gly 690 695 700 TGG AGA GGA AGT ACA GAT ATT ACC ATC CAA GGA GGA GAT GAC GTA TTC 2160 Trp Arg Gly Ser Thr Asp He Thr He Gin Gly Gly Asp Asp Val Phe 705 710 715 720 AAA GAG AAT TAC GTC ACA CTA CCG GGT ACC GTT GAT GAG TGC TAT CCA 2208 Lys Glu Asn Tyr Val Thr Leu Pro Gly Thr Val Asp Glu Cys Tyr Pro 725 730 735 ACG TAT TTA TAT CAG AAA ATA GAT GAG TCG AAA TTA AAA GCT TAT ACC 2256 Thr Tyr Leu Tyr Gin Lys He Asp Glu Ser Lys Leu Lys Ala Tyr Thr 740 745 750 CGT TAT GAA TTA AGA GGG TAT ATC GAA GAT AGT CAA GAC TTA GAA ATC 2304 Arg Tyr Glu Leu Arg Gly Tyr He Glu Asp Ser Gin Asp Leu Glu He 755 760 765 TAT TTG ATC CGT TAC AAT GCA AAA CAC GAA ATA GTA AAT GTG CCA GGC 2352 Tyr Leu He Arg Tyr Asn Ala Lys His Glu He Val Asn Val Pro Gly 770 775 780 ACG GGT TCC TTA TGG CCG CTT TCA GCC CAA AGT CCA ATC GGA AAG TGT '2400 Thr Gly Ser Leu Trp Pro Leu Ser Ala Gin Ser Pro He Gly Lys Cys 785 790 795 800 GGA GAA CCG AAT CGA TGC GCG CCA CAC CTT GAA TGG AAT CCT GAT CTA 2448 Gly Glu Pro Asn Arg Cys Ala Pro His Leu Glu Trp Asn Pro Asp Leu 805 810 815 GAT TGT TCC TGC AGA GAC GGG GAA AAA TGT GCA CAT CAT TCC CAT CAT 2496 Asp Cys Ser Cys Arg Asp Gly Glu Lys Cys Ala His His Ser His His 820 825 830 TTC ACC TTG GAT ATT GAT GTT GGA TGT ACA GAC TTA AAT GAG GAC TTA 2544 Phe Thr Leu Asp He Asp Val Gly Cys Thr Asp Leu Asn Glu Asp Leu 835 840 845 GGT GTA TGG GTG ATA TTC AAG ATT AAG ACG CAA GAT GGC CAT GCA AGA 2592 Gly Val Trp Val He Phe Lys He Lys Thr Gin Asp Gly His Ala Arg 850 855 860 CTA GGG AAT CTA GAG TTT CTC GAA GAG AAA CCA TTA TTA GGG GAA GCA 2640 Leu Gly Asn Leu Glu Phe Leu Glu Glu Lys Pro Leu Leu Gly Glu Ala 865 870 875 880 CTA GCT CGT GTG AAA AGA GCG GAG AAG AAG TGG AGA GAC AAA CGA GAG 2688 Leu .Ala Arg Val Lys Arg Ala Glu Lys Lys Trp Arg Asp Lys Arg Glu 885 890 895 AAA CTG CAG TTG GAA ACA AAT ATT GTT TAT AAA GAG GCA AAA GAA TCT 2736 Lys Leu Gin Leu Glu Thr Asn He Val Tyr Lys Glu Ala Lys Glu Ser 900 905 910 GTA GAT GCT TTA TTT GTA AAC TCT CAA TAT GAT AGA TTA CAA GTG GAT 2784 Val Asp Ala Leu Phe Val Asn Ser Gin Tyr Asp Arg Leu Gin Val Asp 915 920 925 ACG AAC ATC GCG ATG ATT CAT GCG GCA GAT AAA CGC GTT CAT AGA ATC 2832 Thr Asn He Ala Met He His Ala Ala Asp Lys Arg Val His Arg He 930 935 940 CGG GAA GCG TAT CTG CCA GAG TTG TCT GTG ATT CCA GGT GTC AAT GCG 2880 Arg Glu Ala Tyr Leu Pro Glu Leu Ser Val He Pro Gly Val Asn Ala 945 950 955 960 GCC ATT TTC GAA GAA TTA GAG GGA CGT ATT TTT ACA GCG TAT TCC TTA 2928 Ala He Phe Glu Glu Leu Glu Gly Arg He Phe Thr Ala Tyr Ser Leu 965 970 975 TAT GAT GCG AGA AAT GTC ATT AAA AAT GGC GAT TTC AAT AAT GGC TTA 2976 Tyr Asp Ala Arg Asn Val He Lys Asn Gly Asp Phe Asn Asn Gly Leu 980 985 990 TTA TGC TGG AAC GTG AAA GGT CAT GTA GAT GTA GAA GAG CAA AAC AAC 3024 Leu Cys Trp Asn Val Lys Gly His Val Asp Val Glu Glu Gin Asn Asn 995 1000 1005 CAC CGT TCG GTC CTT GTT ATC CCA GAA TGG GAG GCA GAA GTG TCA CAA 3072 His Arg Ser Val Leu Val He Pro Glu Trp Glu Ala Glu Val Ser Gin 1010 1015 1020 GAG GTT CGT GTC TGT CCA GGT CGT GGC TAT ATC CTT CGT GTC ACA GCA 3120 Glu Val Arg Val Cys Pro Gly Arg Gly Tyr He Leu Arg Val Thr Ala 1025 1030 1035 1040 TAT AAA GAG GGA TAT GGA GAG GGC TGC GTA ACG ATC CAT GAG ATC GAA 3168 Tyr Lys Glu Gly Tyr Gly Glu Gly Cys Val Thr He His Glu He Glu 1045 1050 1055 GAC AAT ACA GAC GAA CTG AAA TTC AGC AAC TGT GTA GAA GAG GAA GTA 3216 Asp Asn Thr Asp Glu Leu Lys Phe Ser Asn Cys Val Glu Glu Glu Val 1060 1065 1070 TAT CCA AAC AAC ACA GTA ACG TGT AAT AAT TAT ACT GGG ACT CAA GAA 3264 Tyr Pro Asn Asn Thr Val Thr Cys Asn Asn Tyr Thr Gly Thr Gin Glu 1075 1080 1085 GAA TAT GAG GGT ACG TAC ACT TCT CGT AAT CAA GGA TAT GAC GAA GCC 3312 Glu Tyr Glu Gly Thr Tyr Thr Ser Arg Asn Gin Gly Tyr Asp Glu Ala 1090 1095 1100 TAT GGT AAT AAC CCT TCC GTA CCA GCT GAT TAC GCT TCA GTC TAT GAA 3360 Tyr Gly Asn Asn Pro Ser Val Pro Ala Asp Tyr Ala Ser Val Tyr Glu 1105 1110 1115 1120 GAA AAA TCG TAT ACA GAT GGA CGA AGA GAG AAT CCT TGT GAA TCT AAC 3408 Glu Lys Ser Tyr Thr Asp Gly Arg Arg Glu Asn Pro Cys Glu Ser Asn 1125 1130 1135 AGA GGC TAT GGG GAT TAC ACA CCA CTA CCG GCT GGT TAT GTA ACA AAG 3456 Arg Gly Tyr Gly Asp Tyr Thr Pro Leu Pro Ala Gly Tyr Val Thr Lys 1140 1145 1150 GAT TTA GAG TAC TTC CCA GAG ACC GAT AAG GTA TGG ATT GAG ATC GGA 3504 Asp Leu Glu Tyr Phe Pro Glu Thr Asp Lys Val Trp He Glu He Gly 1155 1160 1165 GAA ACA GAA GGA ACA TTC ATC GTG GAT AGC GTG GAA TTA CTC CTT ATG 3552 Glu Thr Glu Gly Thr Phe He Val Asp Ser Val Glu Leu Leu Leu Met 1170 1175 1180 GAG GAA 3558 Glu Glu 1185 (2) INFORMATION FOR SEQ ID NO: 6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1186 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6: Met Glu He Val Asn Asn Gin Asn Gin Cys Val Pro Tyr Asn Cys Leu 1 5 10 15 Asn Asn Pro Glu Asn Glu He Leu Asp He Glu Arg Ser Asn Ser Thr 20 25 30 Val Ala Thr Asn He Ala Leu Glu He Ser Arg Leu Leu Ala Ser Ala 35 40 45 Thr Pro He Gly Gly He Leu Leu Gly Leu Phe Asp Ala He Trp Gly 50 55 60 Ser He Gly Pro Ser Gin Trp Asp Leu Phe Leu Glu Gin He Glu Leu 65 70 75 80 Leu He Asp Gin Lys He Glu Glu Phe Ala Arg Asn Gin Ala He Ser 85 90 95 Arg Leu Glu Gly He Ser Ser Leu Tyr Gly He Tyr Thr Glu Ala Phe 100 105 110 Arg Glu Trp Glu Ala Asp Pro Thr Asn Pro Ala Leu Lys Glu Glu Met 115 120 125 Arg Thr Gin Phe Asn Asp Met Asn Ser He Leu Val Thr Ala He Pro 130 135 140 Leu Phe Ser Val Gin Asn Tyr Gin Val Pro Phe Leu Ser Val Tyr Val 145 150 155 160 Gin Ala Ala Asn Leu His Leu Ser Val Leu Arg Asp Val Ser Val Phe 165 170 175 Gly Gin Ala Trp Gly Phe Asp He Ala Thr He Asn Ser Arg Tyr Asn 180 185 190 Asp Leu Thr Arg Leu He Pro He Tyr Thr Asp Tyr Ala Val Arg Trp 195 200 205 Tyr Asn Thr Gly Leu Asp Arg Leu Pro Arg Thr Gly Gly Leu Arg Asn 210 215 220 Trp Ala Arg Phe Asn Gin Phe Arg Arg Glu Leu Thr He Ser Val Leu 225 230 235 240 Asp He He Ser Phe Phe Arg Asn Tyr Asp Ser Arg Leu Tyr Pro He 245 250 255 Pro Thr Ser Ser Gin Leu Thr Arg Glu Val Tyr Thr Asp Pro Val He 260 265 270 Asn He Thr Asp Tyr Arg Val Gly Pro Ser Phe Glu Asn He Glu Asn 275 280 285 Ser Ala He Arg Ser Pro His Leu Met Asp Phe Leu Asn Asn Leu Thr 290 295 300 He Asp Thr Asp Leu He Arg Gly Val His Tyr Trp Ala Gly His Arg 305 310 315 320 Val Thr Ser His Phe Thr Gly Ser Ser Gin Val He Thr Thr Pro Gin 325 330 335 Tyr Gly He Thr Ala Asn Ala Glu Pro Arg Arg Thr He Ala Pro Ser 340 345 350 Thr Phe Pro Gly Leu Asn Leu Phe Tyr Arg Thr Leu Ser Asn Pro Phe 355 360 365 Phe Arg Arg Ser Glu Asn He Thr Pro Thr Leu Gly He Asn Val Val 370 375 380 Gin Gly Val Gly Phe He Gin Pro Asn Asn Ala Glu Val Leu Tyr Arg 385 390 395 400 Ser Arg Gly Thr Val Asp Ser Leu Asn Glu Leu Pro He Asp Gly Glu 405 410 415 Asn Ser Leu Val Gly Tyr Ser His Arg Leu Ser His Val Thr Leu Thr 420 425 430 Arg Ser Leu Tyr Asn Thr Asn He Thr Ser Leu Pro Thr Phe Val Trp 435 440 445 Thr His His Ser Ala Thr Asn Thr Asn Thr He Asn Pro Asp He He 450 455 460 Thr Gin He Pro Leu Val Lys Gly Phe Arg Val Trp Gly Gly Thr Ser 465 470 475 480 Val He Thr Gly Pro Gly Phe Thr Gly Gly Asp He Leu Arg Arg Asn 485 490 495 Thr Phe Gly Asp Phe Val Ser Leu Gin Val Asn He Asn Ser Pro He 500 505 510 Thr Gin Arg Tyr Arg Leu Arg Phe Arg Tyr Ala Ser Ser Arg Asp Ala 515 520 525 Arg Val He Val Leu Thr Gly Ala Ala Ser Thr Gly Val Gly Gly Gin 530 535 540 Val Ser Val Asn Met Pro Leu Gin Lys Thr Met Glu He Gly Glu Asn 545 550 555 560 Leu Thr Ser Arg Thr Phe Arg Tyr Thr Asp Phe Ser Asn Pro Phe Ser 565 570 575 Phe Arg Ala Asn Pro Asp He He Gly He Ser Glu Gin Pro Leu Phe 580 585 590 Gly Ala Gly Ser He Ser Ser Gly Glu Leu Tyr He Asp Lys He Glu 595 600 605 He He Leu Ala Asp Ala Thr Phe Glu Ala Glu Ser Asp Leu Glu Arg 610 615 620 Ala Gin Lys Ala Val Asn Ala Leu Phe Thr Ser Ser Asn Gin He Gly 625 630 635 640 Leu Lys Thr Asp Val Thr Asp Tyr His He Asp Gin Val Ser Asn Leu 645 650 655 Val Asp Cys Leu Ser Asp Glu Phe Cys Leu Asp Glu Lys Arg Glu Leu 660 665 670 Ser Glu Lys Val Lys His Ala Lys Arg Leu Ser Asp Glu Arg Asn Leu 675 680 685 Leu Gin Asp Pro Asn Phe Arg Gly He Asn Arg Gin Pro Asp Arg Gly 690 695 700 Trp Arg Gly Ser Thr Asp He Thr He Gin Gly Gly Asp Asp Val Phe 705 710 715 720 Lys Glu Asn Tyr Val Thr Leu Pro Gly Thr Val Asp Glu Cys Tyr Pro 725 730 735 Thr Tyr Leu Tyr Gin Lys He Asp Glu Ser Lys Leu Lys Ala Tyr Thr 740 745 750 Arg Tyr Glu Leu Arg Gly Tyr He Glu Asp Ser Gin Asp Leu Glu He 755 760 765 Tyr Leu He Arg Tyr Asn Ala Lys His Glu He Val Asn Val Pro Gly 770 775 780 Thr Gly Ser Leu Trp Pro Leu Ser Ala Gin Ser Pro He Gly Lys Cys 785 790 795 800 Gly Glu Pro Asn Arg Cys Ala Pro His Leu Glu Trp Asn Pro Asp Leu 805 810 815 Asp Cys Ser Cys Arg Asp Gly Glu Lys Cys Ala His His Ser His His 820 825 830 Phe Thr Leu Asp He Asp Val Gly Cys Thr Asp Leu Asn Glu Asp Leu 835 840 845 Gly Val Trp Val He Phe Lys He Lys Thr Gin Asp Gly His Ala Arg 850 855 860 Leu Gly Asn Leu Glu Phe Leu Glu Glu Lys Pro Leu Leu Gly Glu Ala 865 870 875 880 Leu Ala Arg Val Lys Arg Ala Glu Lys Lys Trp Arg Asp Lys Arg Glu 885 890 895 Lys Leu Gin Leu Glu Thr Asn He Val Tyr Lys Glu Ala Lys Glu Ser 900 905 910 Val Asp Ala Leu Phe Val Asn Ser Gin Tyr Asp Arg Leu Gin Val Asp 915 920 925 Thr Asn He Ala Met He His Ala Ala Asp Lys Arg Val His Arg He 930 935 940 Arg Glu Ala Tyr Leu Pro Glu Leu Ser Val He Pro Gly Val Asn Ala 945 950 955 960 Ala He Phe Glu Glu Leu Glu Gly Arg He Phe Thr Ala Tyr Ser Leu 965 970 975 Tyr Asp Ala Arg Asn Val He Lys Asn Gly Asp Phe Asn Asn Gly Leu 980 985 990 Leu Cys Trp Asn Val Lys Gly His Val Asp Val Glu Glu Gin Asn Asn 995 1000 1005 His Arg Ser Val Leu Val He Pro Glu Trp Glu Ala Glu Val Ser Gin 1010 1015 1020 Glu Val Arg Val Cys Pro Gly Arg Gly Tyr He Leu Arg Val Thr Ala 1025 1030 1035 1040 Tyr Lys Glu Gly Tyr Gly Glu Gly Cys Val Thr He His Glu He Glu 1045 1050 1055 Asp Asn Thr Asp Glu Leu Lys Phe Ser Asn Cys Val Glu Glu Glu Val 1060 1065 1070 Tyr Pro Asn Asn Thr Val Thr Cys Asn Asn Tyr Thr Gly Thr Gin Glu 1075 1080 1085 Glu Tyr Glu Gly Thr Tyr Thr Ser Arg Asn Gin Gly Tyr Asp Glu Ala 1090 1095 1100 Tyr Gly Asn Asn Pro Ser Val Pro Ala Asp Tyr Ala Ser Val Tyr Glu 1105 1110 1115 1120 Glu Lys Ser Tyr Thr Asp Gly Arg Arg Glu Asn Pro Cys Glu Ser Asn 1125 1130 1135 Arg Gly Tyr Gly Asp Tyr Thr Pro Leu Pro Ala Gly Tyr Val Thr Lys 1140 1145 1150 Asp Leu Glu Tyr Phe Pro Glu Thr Asp Lys Val Trp He Glu He Gly 1155 1160 1165 Glu Thr Glu Gly Thr Phe He Val Asp Ser Val Glu Leu Leu Leu Met 1170 1175 1180 Glu Glu 1185 (2) INFORMATION FOR SEQ ID NO: 7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3579 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iii) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Hybrid toxin (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..3579 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7: ATG GAT AAC AAT CCG AAC ATC AAT GAA TGC ATT CCT TAT AAT TGT TTA 48 Met Asp Asn Asn Pro Asn He Asn Glu Cys He Pro Tyr Asn Cys Leu 1 5 10 15 AGT AAC CCT GAA GTA GAA GTA TTA GGT GGA GAA AGA ATA GAA ACT GGT 96 Ser Asn Pro Glu Val Glu Val Leu Gly Gly Glu Arg He Glu Thr Gly 20 25 30 TAC ACC CCA ATC GAT ATT TCC TTG TCG CTA ACG CAA TTT CTT TTG AGT 144 Tyr Thr Pro He Asp He Ser Leu Ser Leu Thr Gin Phe Leu Leu Ser 35 40 45 GAA TTT GTT CCC GGT GCT GGA TTT GTG TTA GGA CTA GTT GAT ATA ATA 192 Glu Phe Val Pro Gly Ala Gly Phe Val Leu Gly Leu Val Asp He He 50 " 55 60 TGG GGA ATT TTT GGT CCC TCT CAA TGG GAC GCA TTT CTT GTA CAA ATT 240 Trp Gly He Phe Gly Pro Ser Gin Trp Asp Ala Phe Leu Val Gin He 65 70 75 80 GAA CAG TTA ATT AAC CAA AGA ATA GAA GAA TTC GCT AGG AAC CAA GCC 288 Glu Gin Leu He Asn Gin Arg He Glu Glu Phe Ala Arg Asn Gin Ala 85 90 95 ATT TCT AGA TTA GAA GGA CTA AGC AAT CTT TAT CAA ATT TAC GCA GAA 336 He Ser Arg Leu Glu Gly Leu Ser Asn Leu Tyr Gin He Tyr Ala Glu 100 105 110 TCT TTT AGA GAG TGG GAA GCA GAT CCT ACT AAT CCA GCA TTA AGA GAA 384 Ser Phe Arg Glu Trp Glu Ala Asp Pro Thr Asn Pro Ala Leu Arg Glu 115 120 125 GAG ATG CGT ATT CAA TTC AAT GAC ATG AAC AGT GCC CTT ACA ACC GCT 432 Glu Met Arg He Gin Phe Asn Asp Met Asn Ser Ala Leu Thr Thr Ala 130 135 140 ATT CCT CTT TTT GCA GTT CAA AAT TAT CAA GTT CCT CTT TTA TCA GTA 480 He Pro Leu Phe Ala Val Gin Asn Tyr Gin Val Pro Leu Leu Ser Val 145 150 155 160 TAT GTT CAA GCT GCA AAT TTA CAT TTA TCA GTT TTG AGA GAT GTT TCA 528 Tyr Val Gin Ala Ala Asn Leu His Leu Ser Val Leu Arg Asp Val Ser 165 170 175 GTG TTT GGA CAA AGG TGG GGA TTT GAT GCC GCG ACT ATC AAT AGT CGT 576 Val Phe Gly Gin Arg Trp Gly Phe Asp Ala Ala Thr He Asn Ser Arg 180 185 190 TAT AAT GAT TTA ACT AGG CTT ATT GGC AAC TAT ACA GAT CAT GCT GTA 624 Tyr Asn Asp Leu Thr Arg Leu He Gly Asn Tyr Thr Asp His Ala Val 195 200 205 CGC TGG TAC AAT ACG GGA TTA GAG CGT GTA TGG GGA CCG GAT TCT AGA 672 Arg Trp Tyr Asn Thr Gly Leu Glu Arg Val Trp Gly Pro Asp Ser Arg 210 215 220 GAT TGG ATA AGA TAT AAT CAA TTT AGA AGA GAA TTA ACA CTA ACT GTA 720 Asp Trp He Arg Tyr Asn Gin Phe Arg Arg Glu Leu Thr Leu Thr Val 225 230 235 240 TTA GAT ATC GTT TCT CTA TTT CCG AAC TAT GAT AGT AGA ACG TAT CCA 768 Leu Asp He Val Ser Leu Phe Pro Asn Tyr Asp Ser Arg Thr Tyr Pro 245 250 255 ATT CGA ACA GTT TCC CAA TTA ACA AGA GAA ATT TAT ACA AAC CCA GTA 816 He Arg Thr Val Ser Gin Leu Thr Arg Glu He Tyr Thr Asn Pro Val 260 265 270 TTA GAA AAT TTT GAT GGT AGT TTT CGA GGC TCG GCT CAG GGC ATA GAA 864 Leu Glu Asn Phe Asp Gly Ser Phe Arg Gly Ser Ala Gin Gly He Glu 275 280 285 GGA AGT ATT AGG AGT CCA CAT TTG ATG GAT ATA CTT AAC AGT ATA ACC 912 Gly Ser He Arg Ser Pro His Leu Met Asp He Leu Asn Ser He Thr 290 295 300 ATC TAT ACG GAT GCT CAT AGA GGA GAA TAT TAT TGG TCA GGG CAT CAA 960 He Tyr Thr Asp Ala His Arg Gly Glu Tyr Tyr Trp Ser Gly His Gin 305 310 315 320 ATA ATG GCT TCT CCT GTA GGG TTT TCG GGG CCA GAA TTC ACT TTT CCG 1008 He Met Ala Ser Pro Val Gly Phe Ser Gly Pro Glu Phe Thr Phe Pro 325 330 335 CTA TAT GGA ACT ATG GGA AAT GCA GCT CCA CAA CAA CGT ATT GTT GCT 1056 Leu Tyr Gly Thr Met Gly Asn Ala Ala Pro Gin Gin Arg He Val Ala 340 345 350 CAA CTA GGT CAG GGC GTG TAT AGA ACA TTA TCG TCC ACT TTA TAT AGA 1104 Gin Leu Gly Gin Gly Val Tyr Arg Thr Leu Ser Ser Thr Leu Tyr Arg 355 360 365 AGA CCT TTT AAT ATA GGG ATA AAT AAT CAA CAA CTA TCT GTT CTT GAC 1152 Arg Pro Phe Asn He Gly He Asn Asn Gin Gin Leu Ser Val Leu Asp 370 375 380 GGG ACA GAA TTT GCT TAT GGA ACC TCC TCA AAT TTG CCA TCC GCT GTA 1200 Gly Thr Glu Phe Ala Tyr Gly Thr Ser Ser Asn Leu Pro Ser Ala Val 385 390 395 400 TAC AGA AAA AGC GGA ACG GTA GAT TCG CTG GAT GAA ATA CCG CCA CAG 1248 Tyr Arg Lys Ser Gly Thr Val Asp Ser Leu Asp Glu He Pro Pro Gin 405 410 415 AAT AAC AAC GTG CCA CCT AGG CAA GGA TTT AGT CAT CGA TTA AGC CAT 1296 Asn Asn Asn Val Pro Pro Arg Gin Gly Phe Ser His Arg Leu Ser His 420 425 430 GTT TCA ATG TTT CGT TCA GGC TTT AGT AAT AGT AGT GTA AGT ATA ATA 1344 Val Ser Met Phe Arg Ser Gly Phe Ser Asn Ser Ser Val Ser He He 435 440 445 AGA GCT CCT ATG TTC TCT TGG ATA CAT CGT AGT GCA ACT CTT ACA AAT 1392 Arg Ala Pro Met Phe Ser Trp He His Arg Ser Ala Thr Leu Thr Asn 450 455 460 ACA ATT GAT CCA GAG AGA ATT AAT CAA ATA CCT TTA GTG AAA GGA TTT 1440 Thr He Asp Pro Glu Arg He Asn Gin He Pro Leu Val Lys Gly Phe 465 470 475 480 AGA GTT TGG GGG GGC ACC TCT GTC ATT ACA GGA CCA GGA TTT ACA GGA 1488 Arg Val Trp Gly Gly Thr Ser Val He Thr Gly Pro Gly Phe Thr Gly 485 490 495 GGG GAT ATC CTT CGA AGA AAT ACC TTT GGT GAT TTT GTA TCT CTA CAA 1536 Gly Asp He Leu Arg Arg Asn Thr Phe Gly Asp Phe Val Ser Leu Gin 500 505 510 GTC AAT ATT AAT TCA CCA ATT ACC CAA AGA TAC CGT TTA AGA TTT CGT 1584 Val Asn He Asn Ser Pro He Thr Gin Arg Tyr Arg Leu Arg Phe Arg 515 520 525 TAC GCT TCC AGT AGG GAT GCA CGA GTT ATA GTA TTA ACA GGA GCG GCA 1632 Tyr Ala Ser Ser Arg Asp Ala Arg Val He Val Leu Thr Gly Ala Ala 530 535 540 TCC ACA GGA GTG GGA GGC CAA GTT AGT GTA AAT ATG CCT CTT CAG AAA 1680 Ser Thr Gly Val Gly Gly Gin Val Ser Val Asn Met Pro Leu Gin Lys 545 550 555 560 ACT ATG GAA ATA GGG GAG AAC TTA ACA TCT AGA ACA TTT AGA TAT ACC 1728 Thr Met Glu He Gly Glu Asn Leu Thr Ser Arg Thr Phe Arg Tyr Thr 565 570 575 GAT TTT AGT AAT CCT TTT TCA TTT AGA GCT AAT CCA GAT ATA ATT GGG 1776 Asp Phe Ser Asn Pro Phe Ser Phe Arg Ala Asn Pro Asp He He Gly 580 585 590 ATA AGT GAA CAA CCT CTA TTT GGT GCA GGT TCT ATT AGT AGC GGT GAA 1824 He Ser Glu Gin Pro Leu Phe Gly Ala Gly Ser He Ser Ser Gly Glu 595 600 605 CTT TAT ATA GAT AAA ATT GAA ATT ATT CTA GCA GAT GCA ACA TTT GAA 1872 Leu Tyr He Asp Lys He Glu He He Leu Ala Asp Ala Thr Phe Glu 610 615 620 GCA GAA TCT GAT TTA GAA AGA GCA CAA AAG GCG GTG AAT GCC CTG TTT 1920 Ala Glu Ser Asp Leu Glu Arg Ala Gin Lys Ala Val Asn Ala Leu Phe 625 630 635 640 ACT TCT TCC AAT CAA ATC GGG TTA AAA ACC GAT GTG ACG GAT TAT CAT 1968 Thr Ser Ser Asn Gin He Gly Leu Lys Thr Asp Val Thr Asp Tyr His 645 650 655 ATT GAT CAA GTA TCC AAT TTA GTG GAT TGT TTA TCA GAT GAA TTT TGT 2016 He Asp Gin Val Ser Asn Leu Val Asp Cys Leu Ser Asp Glu Phe Cys 660 665 670 CTG GAT GAA AAG CGA GAA TTG TCC GAG AAA GTC AAA CAT GCG AAG CGA 2064 Leu Asp Glu Lys Arg Glu Leu Ser Glu Lys Val Lys His Ala Lys Arg 675 680 685 CTC AGT GAT GAG CGG AAT TTA CTT CAA GAT CCA AAC TTC AGA GGG ATC 2112 Leu Ser Asp Glu Arg Asn Leu Leu Gin Asp Pro Asn Phe Arg Gly He 690 695 700 AAT AGA CAA CCA GAC CGT GGC TGG AGA GGA AGT ACA GAT ATT ACC ATC 2160 Asn Arg Gin Pro Asp Arg Gly Trp Arg Gly Ser Thr Asp He Thr He 705 710 715 720 CAA GGA GGA GAT GAC GTA TTC AAA GAG AAT TAC GTC ACA CTA CCG GGT 2208 Gin Gly Gly Asp Asp Val Phe Lys Glu Asn Tyr Val Thr Leu Pro Gly 725 730 735 ACC GTT GAT GAG TGC TAT CCA ACG TAT TTA TAT CAG AAA ATA GAT GAG 2256 Thr Val Asp Glu Cys Tyr Pro Thr Tyr Leu Tyr Gin Lys He Asp Glu 740 745 750 TCG AAA TTA AAA GCT TAT ACC CGT TAT GAA TTA AGA GGG TAT ATC GAA 2304 Ser Lys Leu Lys Ala Tyr Thr Arg Tyr Glu Leu Arg Gly Tyr He Glu 755 760 765 GAT AGT CAA GAC TTA GAA ATC TAT TTG ATC CGT TAC AAT GCA AAA CAC 2352 Asp Ser Gin Asp Leu Glu He Tyr Leu He Arg Tyr Asn Ala Lys His 770 775 780 GAA ATA GTA AAT GTG CCA GGC ACG GGT TCC TTA TGG CCG CTT TCA GCC 2400 Glu He Val Asn Val Pro Gly Thr Gly Ser Leu Trp Pro Leu Ser Ala 785 790 795 800 CAA AGT CCA ATC GGA AAG TGT GGA GAA CCG AAT CGA TGC GCG CCA CAC 2448 Gin Ser Pro He Gly Lys Cys Gly Glu Pro Asn Arg Cys Ala Pro His 805 810 815 CTT GAA TGG AAT CCT GAT CTA GAT TGT TCC TGC AGA GAC GGG GAA AAA 2496 Leu Glu Trp Asn Pro Asp Leu Asp Cys Ser Cys Arg Asp Gly Glu Lys 820 825 830 TGT GCA CAT CAT TCC CAT CAT TTC ACC TTG GAT ATT GAT GTT GGA TGT 2544 Cys Ala His His Ser His His Phe Thr Leu Asp He Asp Val Gly Cys 835 840 845 ACA GAC TTA AAT GAG GAC TTA GGT GTA TGG GTG ATA TTC AAG ATT AAG 2592 Thr Asp Leu Asn Glu Asp Leu Gly Val Trp Val He Phe Lys He Lys 850 855 860 ACG CAA GAT GGC CAT GCA AGA CTA GGG AAT CTA GAG TTT CTC GAA GAG 2640 Thr Gin Asp Gly His Ala Arg Leu Gly Asn Leu Glu Phe Leu Glu Glu 865 870 875 880 AAA CCA TTA TTA GGG GAA GCA CTA GCT CGT GTG AAA AGA GCG GAG AAG 2688 Lys Pro Leu Leu Gly Glu Ala Leu Ala Arg Val Lys Arg Ala Glu Lys 885 890 895 * AAG TGG AGA GAC AAA CGA GAG AAA CTG CAG TTG GAA ACA AAT ATT GTT 2736 Lys Trp Arg Asp Lys Arg Glu Lys Leu Gin Leu Glu Thr Asn He Val 900 905 910 TAT AAA GAG GCA AAA GAA TCT GTA GAT GCT TTA TTT GTA AAC TCT CAA 2784 Tyr Lys Glu Ala Lys Glu Ser Val Asp Ala Leu Phe Val Asn Ser Gin 915 920 925 TAT GAT AGA TTA CAA GTG GAT ACG AAC ATC GCG ATG ATT CAT GCG GCA 2832 Tyr Asp Arg Leu Gin Val Asp Thr Asn He Ala Met He His Ala Ala 930 935 940 GAT AAA CGC GTT CAT AGA ATC CGG GAA GCG TAT CTG CCA GAG TTG TCT 2880 Asp Lys Arg Val His Arg He Arg Glu Ala Tyr Leu Pro Glu Leu Ser 945 950 955 960 GTG ATT CCA GGT GTC AAT GCG GCC ATT TTC GAA GAA TTA GAG GGA CGT 2928 Val He Pro Gly Val Asn Ala Ala He Phe Glu Glu Leu Glu Gly Arg 965 970 975 ATT TTT ACA GCG TAT TCC TTA TAT GAT GCG AGA AAT GTC ATT AAA AAT 2976 He Phe Thr Ala Tyr Ser Leu Tyr Asp Ala Arg Asn Val He Lys Asn 980 985 990 GGC GAT TTC AAT AAT GGC TTA TTA TGC TGG AAC GTG AAA GGT CAT GTA 3024 Gly Asp Phe Asn Asn Gly Leu Leu Cys Trp Asn Val Lys Gly His Val 995 1000 1005 GAT GTA GAA GAG CAA AAC AAC CAC CGT TCG GTC CTT GTT ATC CCA GAA 3072 Asp Val Glu Glu Gin Asn Asn His Arg Ser Val Leu Val He Pro Glu 1010 1015 1020 TGG GAG GCA GAA GTG TCA CAA GAG GTT CGT GTC TGT CCA GGT CGT GGC 3120 Trp Glu Ala Glu Val Ser Gin Glu Val Arg Val Cys Pro Gly Arg Gly 1025 1030 1035 1040 TAT ATC CTT CGT GTC ACA GCA TAT AAA GAG GGA TAT GGA GAG GGC TGC 3168 Tyr He Leu Arg Val Thr Ala Tyr Lys Glu Gly Tyr Gly Glu Gly Cys 1045 1050 1055 GTA ACG ATC CAT GAG ATC GAA GAC AAT ACA GAC GAA CTG AAA TTC AGC 3216 Val Thr He His Glu He Glu Asp Asn Thr Asp Glu Leu Lys Phe Ser 1060 1065 1070 AAC TGT GTA GAA GAG GAA GTA TAT CCA AAC AAC ACA GTA ACG TGT AAT 3264 Asn Cys Val Glu Glu Glu Val Tyr Pro Asn Asn Thr Val Thr Cys Asn 1075 1080 1085 AAT TAT ACT GGG ACT CAA GAA GAA TAT GAG GGT ACG TAC ACT TCT CGT 3312 Asn Tyr Thr Gly Thr Gin Glu Glu Tyr Glu Gly Thr Tyr Thr Ser Arg 1090 1095 1100 AAT CAA GGA TAT GAC GAA GCC TAT GGT AAT AAC CCT TCC GTA CCA GCT 3360 Asn Gin Gly Tyr Asp Glu Ala Tyr Gly Asn Asn Pro Ser Val Pro Ala 1105 1110 1115 1120 GAT TAC GCT TCA GTC TAT GAA GAA AAA TCG TAT ACA GAT GGA CGA AGA 3408 Asp Tyr Ala Ser Val Tyr Glu Glu Lys Ser Tyr Thr Asp Gly Arg Arg 1125 1130 1135 GAG AAT CCT TGT GAA TCT AAC AGA GGC TAT GGG GAT TAC ACA CCA CTA 3456 Glu Asn Pro Cys Glu Ser Asn Arg Gly Tyr Gly Asp Tyr Thr Pro Leu 1140 1145 1150 CCG GCT GGT TAT GTA ACA AAG GAT TTA GAG TAC TTC CCA GAG ACC GAT 3504 Pro Ala Gly Tyr Val Thr Lys Asp Leu Glu Tyr Phe Pro Glu Thr Asp 1155 1160 1165 AAG GTA TGG ATT GAG ATC GGA GAA ACA GAA GGA ACA TTC ATC GTG GAT 3552 Lys Val Trp He Glu He Gly Glu Thr Glu Gly Thr Phe He Val Asp 1170 1175 1180 AGC GTG GAA TTA CTC CTT ATG GAG GAA 3579 Ser Val Glu Leu Leu Leu Met Glu Glu 1185 1190 (2) INFORMATION FOR SEQ ID NO: 8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1193 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8: Met Asp Asn Asn Pro Asn He Asn Glu Cys He Pro Tyr Asn Cys Leu 1 5 10 15 Ser Asn Pro Glu Val Glu Val Leu Gly Gly Glu Arg He Glu Thr Gly 20 25 30 Tyr Thr Pro He Asp He Ser Leu Ser Leu Thr Gin Phe Leu Leu Ser 35 40 45 Glu Phe Val Pro Gly Ala Gly Phe Val Leu Gly Leu Val Asp He He 50 55 60 Trp Gly He Phe Gly Pro Ser Gin Trp Asp Ala Phe Leu Val Gin He 65 70 75 80 Glu Gin Leu He Asn Gin Arg He Glu Glu Phe Ala Arg Asn Gin Ala 85 90 95 He Ser Arg Leu Glu Gly Leu Ser Asn Leu Tyr Gin He Tyr Ala Glu 100 105 110 Ser Phe Arg Glu Trp Glu Ala Asp Pro Thr Asn Pro Ala Leu Arg Glu 115 120 125 Glu Met Arg He Gin Phe Asn Asp Met Asn Ser Ala Leu Thr Thr Ala 130 135 140 He Pro Leu Phe Ala Val Gin Asn Tyr Gin Val Pro Leu Leu Ser Val 145 150 155 160 Tyr Val Gin Ala Ala Asn Leu His Leu Ser Val Leu Arg Asp Val Ser 165 170 175 Val Phe Gly Gin Arg Trp Gly Phe Asp Ala Ala Thr He Asn Ser Arg 180 185 190 Tyr Asn Asp Leu Thr Arg Leu He Gly Asn Tyr Thr Asp His Ala Val 195 200 205 Arg Trp Tyr Asn Thr Gly Leu Glu Arg Val Trp Gly Pro Asp Ser Arg 210 215 220 Asp Trp He Arg Tyr Asn Gin Phe Arg Arg Glu Leu Thr Leu Thr Val 225 230 235 240 Leu Asp He Val Ser Leu Phe Pro Asn Tyr Asp Ser Arg Thr Tyr Pro 245 250 255 He Arg Thr Val Ser Gin Leu Thr Arg Glu He Tyr Thr Asn Pro Val 260 265 270 Leu Glu Asn Phe Asp Gly Ser Phe Arg Gly Ser Ala Gin Gly He Glu 275 280 285 Gly Ser He Arg Ser Pro His Leu Met Asp He Leu Asn Ser He Thr 290 295 300 He Tyr Thr Asp Ala His Arg Gly Glu Tyr Tyr Trp Ser Gly His Gin 305 310 315 320 He Met Ala Ser Pro Val Gly Phe Ser Gly Pro Glu Phe Thr Phe Pro 325 330 335 Leu Tyr Gly Thr Met Gly Asn Ala Ala Pro Gin Gin Arg He Val Ala 340 345 350 Gin Leu Gly Gin Gly Val Tyr Arg Thr Leu Ser Ser Thr Leu Tyr Arg 355 360 365 Arg Pro Phe Asn He Gly He Asn Asn Gin Gin Leu Ser Val Leu Asp 370 375 380 Gly Thr Glu Phe Ala Tyr Gly Thr Ser Ser Asn Leu Pro Ser Ala Val 385 390 395 400 Tyr Arg Lys Ser Gly Thr Val Asp Ser Leu Asp Glu He Pro Pro Gin 405 410 415 Asn Asn Asn Val Pro Pro Arg Gin Gly Phe Ser His Arg Leu Ser His 420 425 430 Val Ser Met Phe Arg Ser Gly Phe Ser Asn Ser Ser Val Ser He He 435 440 445 Arg Ala Pro Met Phe Ser Trp He His Arg Ser Ala Thr Leu Thr Asn 450 455 460 Thr He Asp Pro Glu Arg He Asn Gin He Pro Leu Val Lys Gly Phe 465 470 475 480 Arg Val Trp Gly Gly Thr Ser Val He Thr Gly Pro Gly Phe Thr Gly 485 490 495 Gly Asp He Leu Arg Arg Asn Thr Phe Gly Asp Phe Val Ser Leu Gin 500 505 510 Val Asn He Asn Ser Pro He Thr Gin Arg Tyr Arg Leu Arg Phe Arg 515 520 525 Tyr Ala Ser Ser Arg Asp Ala Arg Val He Val Leu Thr Gly Ala Ala 530 535 540 Ser Thr Gly Val Gly Gly Gin Val Ser Val Asn Met Pro Leu Gin Lys 545 550 555 560 Thr Met Glu He Gly Glu Asn Leu Thr Ser Arg Thr Phe Arg Tyr Thr 565 570 575 Asp Phe Ser Asn Pro Phe Ser Phe Arg Ala Asn Pro Asp He He Gly 580 585 590 He Ser Glu Gin Pro Leu Phe Gly Ala Gly Ser He Ser Ser Gly Glu 595 600 605 Leu Tyr He Asp Lys He Glu He He Leu Ala Asp Ala Thr Phe Glu 610 615 620 Ala Glu Ser Asp Leu Glu Arg Ala Gin Lys Ala Val Asn Ala Leu Phe 625 630 635 640 Thr Ser Ser Asn Gin He Gly Leu Lys Thr Asp Val Thr Asp Tyr His 645 650 655 He Asp Gin Val Ser Asn Leu Val Asp Cys Leu Ser Asp Glu Phe Cys 660 665 670 Leu Asp Glu Lys Arg Glu Leu Ser Glu Lys Val Lys His Ala Lys Arg 675 680 685 Leu Ser Asp Glu Arg Asn Leu Leu Gin Asp Pro Asn Phe Arg Gly He 690 695 700 Asn Arg Gin Pro Asp Arg Gly Trp Arg Gly Ser Thr Asp He Thr He 705 710 715 720 Gin Gly Gly Asp Asp Val Phe Lys Glu Asn Tyr Val Thr Leu Pro Gly 725 730 735 Thr Val Asp Glu Cys Tyr Pro Thr Tyr Leu Tyr Gin Lys He Asp Glu 740 745 750 Ser Lys Leu Lys Ala Tyr Thr Arg Tyr Glu Leu Arg Gly Tyr He Glu 755 760 765 Asp Ser Gin Asp Leu ;Glu He Tyr Leu He Arg Tyr Asn Ala Lys His 770 ~ 775 780 Glu He Val Asn Val Pro Gly Thr Gly Ser Leu Trp Pro Leu Ser Ala 785 790 795 800 Gin Ser Pro He Gly Lys Cys Gly Glu Pro Asn Arg Cys Ala Pro His 805 810 815 Leu Glu Trp Asn Pro Asp Leu Asp Cys Ser Cys Arg Asp Gly Glu Lys 820 825 830 Cys Ala His His Ser His His Phe Thr Leu Asp He Asp Val Gly Cys 835 840 845 Thr Asp Leu Asn Glu Asp Leu Gly Val Trp Val He Phe Lys He Lys 850 855 860 Thr Gin Asp Gly His Ala Arg Leu Gly Asn Leu Glu Phe Leu Glu Glu 865 870 875 880 Lys Pro Leu Leu Gly Glu Ala Leu Ala Arg Val Lys Arg Ala Glu Lys 885 890 895 Lys Trp Arg Asp Lys Arg Glu Lys Leu Gin Leu Glu Thr Asn He Val 900 905 910 Tyr Lys Glu Ala Lys Glu Ser Val Asp Ala Leu Phe Val Asn Ser Gin 915 920 925 Tyr Asp Arg Leu Gin Val Asp Thr Asn He Ala Met He His Ala Ala 930 935 940 Asp Lys Arg Val His Arg He Arg Glu Ala Tyr Leu Pro Glu Leu Ser 945 950 955 960 Val He Pro Gly Val Asn Ala Ala He Phe Glu Glu Leu Glu Gly Arg 965 970 975 He Phe Thr Ala Tyr Ser Leu Tyr Asp Ala Arg Asn Val He Lys Asn 980 985 990 Gly Asp Phe Asn Asn Gly Leu Leu Cys Trp Asn Val Lys Gly His Val 995 1000 1005 Asp Val Glu Glu Gin Asn Asn His Arg Ser Val Leu Val He Pro Glu 1010 1015 1020 Trp Glu Ala Glu Val Ser Gin Glu Val Arg Val Cys Pro Gly Arg Gly 1025 1030 1035 1040 Tyr He Leu Arg Val Thr Ala Tyr Lys Glu Gly Tyr Gly Glu Gly Cys 1045 1050 1055 Val Thr He His Glu He Glu Asp Asn Thr Asp Glu Leu Lys Phe Ser 1060 1065 1070 Asn Cys Val Glu Glu Glu Val Tyr Pro Asn Asn Thr Val Thr Cys Asn 1075 1080 1085 Asn Tyr Thr Gly Thr Gin Glu Glu Tyr Glu Gly Thr Tyr Thr Ser Arg 1090 1095 1100 Asn Gin Gly Tyr Asp Glu Ala Tyr Gly Asn Asn Pro Ser Val Pro Ala 1105 1110 1115 ' 1120 Asp Tyr Ala Ser Val Tyr Glu Glu Lys Ser Tyr Thr Asp Gly Arg Arg 1125 1130 1135 Glu Asn Pro Cys Glu Ser Asn Arg Gly Tyr Gly Asp Tyr Thr Pro Leu 1140 1145 1150 Pro Ala Gly Tyr Val Thr Lys Asp Leu Glu Tyr Phe Pro Glu Thr Asp 1155 1160 1165 Lys Val Trp He Glu He Gly Glu Thr Glu Gly Thr Phe He Val Asp 1170 1175 1180 Ser Val Glu Leu Leu Leu Met Glu Glu 1185 1190

Claims: CLAIMS 1. B.t. hybrid toxin fragment comprising at its C-terminal domain HI of a first Cry protein or a part of the domain or a protein substantially similar to the domain, with the proviso that the N-terminal region of the fragment is the N-terminal region of a second Cry protein or a part of the region or a protein substantially similar to the region. 2. B.t. hybrid toxin fragment according to claim 1, which binds to a binding site in an insect gut which is different to the site bound by the protein from which the said domain HI is derived. 3. B.t. hybrid toxin fragment according to claim 2, which does not bind to the CrylC binding site and which comprises at its C-terminal domain IQ of CrylC or a part of the domain or a protein substantially similar to the domain; or which does not bind to the CrylA binding site and which comprises at its C-teπninal domain HI of CrylA or a part of the domain or a protein substantially similar to the domain. 4. Toxin fragment according to any preceding claim, which comprises at its N-terminal the N-terminal region of a protein selected from the group consisting of: CryΙA(a), CryIA(b) CryΙA(c), CrylB, CrylC, CrylD, CrylE, CrylF, CrylG, Cryffl, CryllA, CryllB, CryllC, CrylllA, CrylllB, CryΙIIB(b), CrylVA, CrylNB, CryINC, CryIND, CYTA, CryXl(mC), CryX2(IIID), CryX3, CryN, and CryX4; or a part of the region, or a protein substantially similar to the region. 5. Toxin fragment according to any preceding claim, wherein the C-terminal of the fragment is domain HI of CrylC or CrylA or a part of the domain or a protein substantially similar to the domain. 6. Toxin fragment according to any preceding claim which comprises domain II of CrylE CrylB, CrylD or CrylA, or a part of the domain or a protein substantially similar to the domain, and domain HI of CrylC or a part of the said domain HI or a protein substantially similar to the said domain IQ. 7. Toxin fragment according to any preceding claim, which comprises domains I and II of CrylE, CrylB, CrylD or CrylA or a part thereof or a protein substantially similar to the said domains, and domain HI of CrylC or a part thereof or a protein substantially similar to the said domain HI. 8. Toxin fragment according to any preceding claim, comprising a region at its C- teπninus comprising the sequence from amino acid position 454 to position 602 of Cry IC, or a sequence substantially similar to the said sequence. 9. Toxin fragment according to the preceding claim, comprising a region at its C- terminus comprising the sequence from amino acid position 478 to 602 of Cry IC, or a sequence substantially similar to the said sequence. 10. Toxin fragment comprising an amino acid sequence from about amino acid 1 to about amino acid 620 in SEQ ID No. 6, or toxin fragment having an amino acid sequence from about amino acid 1 to about amino acid 620 in SEQ ID No. 6, wherein with respect to the said sequence, at least one of the following alterations is present: He at position 609 is replaced with Leu; Ala at position 618 is replaced with Glu; Ser at position 620 is replaced with Tyr. 11. Toxin fragment comprising an amino acid sequence from about amino acid 1 to about amino acid 627 in SEQ ID No. 8, or toxin fragment having an amino acid sequence from about amino acid 1 to about amino acid 627 in SEQ ID No. 8, wherein with respect to the said sequence, at least one of the following alterations is present: He at position 617 is replaced with Leu; Ala at position 625 is replaced with Glu; Ser at position 627 is replaced with Tyr. 12. A hybrid toxin comprising the fragment of any one of the preceding claims, ora toxin at least 85% similar to such a hybrid toxin which has substantially similar insecticidal activity or receptor binding properties. 13. Pure proteins which are at least 90% identical to the toxin fragments or hybrid toxins of any one of claims 1-12. 14. Recombinant DNA comprising a sequence encoding a protein having an amino acid sequence of the proteins as claimed in any one of claims 1-13. 15. Recombinant DNA comprising the sequence from about nucleotide 1 to about nucleotide 1860 given in SEQ ID. No. 5 or DNA similar thereto encoding a substantially similar protein, or recombinant DNA comprising the sequence from about nucleotide 1 to about nucleotide 1881 in SEQ ID No. 7 or DNA similar thereto encoding a substantially similar protein. 16. Recombinant DNA according to either of claims 14 or 15, which further encodes a protein having herbicide resistance, plant growth-promoting, anti-fungal, anti bacterial, anti¬ viral and/or anti-nematode properties. 17. Recombinant DNA according to any one of claims 14 to 16 which is modified in that known mRNA instability motifs or polyadenylation signals are removed and/or codons which are preferred by the organism into which the recombinant DNA is to be inserted are used so that expression of the thus modified DNA in the said organism yields substantially similar protein to that obtained by expression of the unmodified recombinant DNA in the organism in which the protein components of the hybrid toxin or toxin fragments are endogenous. 18. A DNA sequence which is complementary to one which hybridizes under stringent conditions with the DNA of any one of claims 14 to 17. 19. A vector containing a DNA sequence as claimed in any one of claims 14 to 18. 20. A plant or micro-organism which includes, and enables expression of, the DNA of any one of claims 14-18 or the vector of claim 19. 21. Plants transformed with recombinant DNA as claimed in any one of claims 14 to 18, the progeny of such plants which contain the DNA stably incorporated and hereditable in a Mendelian manner, and/or the seeds of such plants and such progeny. 22. Protein derived from expression of the DNA as claimed in any one of claims 14 to 18, and insecticidal protein produced by expression of the recombinant DNA within plants as claimed in claim 21. 23. An insecticidal composition containing one or more of the proteins as claimed in any one of claims 1-13 and 22. 24. A process for combatting insects which comprises exposing them to proteins or compositions as claimed in any one of claims 1-13, 22 and 23 or the micro-organism of claim 20. 25. An extraction process for obtaining insecticidal proteins, as claimed in any one of claims 1-13 or claim 22, from organic material containing them comprising submitting the material to maceration and solvent extraction, characterized in that the material is a micro¬ organism.

Inventors: BOSCH HENDRIK JAN, STIEKEMA WILLEM JOHANNES, BOSCH, HENDRIK, JAN, STIEKEMA, WILLEM, JOHANNES
Applicants: BOSCH HENDRIK JAN, SANDOZ AG, SANDOZ LTD, STIEKEMA WILLEM JOHANNES, BOSCH, HENDRIK, JAN, SANDOZ LTD., SANDOZ-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT MBH, SANDOZ-PATENT-GMBH, STIEKEMA, WILLEM, JOHANNES
Application year: 1994
Main classification: C12N15
IPC codes: A01M1, A01N37, A01N63, C07K14, C07K19, C12N15